JenYii的个人主页 - 老虎社区

JenYii

JenYii

暂无个人介绍

IP属地：未知

331关注

12粉丝

0主题

0勋章

2021-12-06

Ok

Why Moderna Is the Biggest Winner From COVID Boosters So Far<blockquote>为什么Moderna是迄今为止COVID加强剂的最大赢家</blockquote>

2021-08-09

Like & comment, please………👆🏻🙏🏻

BioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid<blockquote>BioNTech股价因盈利大幅增长而上涨；公司的目光超越了新冠疫情</blockquote>

2021-08-08

Like & comment, please………👆🏻🙏🏻

SEC Moves First DeFi Unregistered Securities Lawsuit<blockquote>SEC提起首起DeFi未注册证券诉讼</blockquote>

2021-08-01

Please like and comment 🙏🏻

抱歉，原内容已删除

2021-08-01

Like & comment, please………….👆🏻🙏🏻

抱歉，原内容已删除

2021-07-31

Please like ……….………………….👆🏻🙏🏻

抱歉，原内容已删除

2021-06-20

🙏🏻🙏🏻🙏🏻

2021-06-18

Read the safety before flying to the moon 🚀🚀🚀

2021-06-17

一分一毫清清楚楚

2021-06-16

Lastly, buy!

2021-06-14

🙏🏻🙏🏻🙏🏻

2021-06-11

🤨🤨🤨

2021-05-21

[Cool] [Cool] [Cool]

2021-05-19

💭💭💭

2021-05-15

The choice is yours

2021-05-14

Putting money in a bank or buying the bank shares?

2021-05-10

Fun fact

2021-05-09

母亲节快乐 ! Happy Mother’s Day !🤎♥️❤️🧡💛💚💙💜🤍

2021-05-06

😎🥸🤓

2021-05-05

Educated them for what they are not learning in school

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3559395309338899","uuid":"3559395309338899","gmtCreate":1596349342614,"gmtModify":1612695532145,"name":"JenYii","pinyin":"jenyii","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":12,"headSize":331,"tweetSize":38,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.41%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.07","exceedPercentage":"80.20%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":608534193,"gmtCreate":1638756985400,"gmtModify":1638756985492,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/608534193","repostId":"1125593879","repostType":4,"repost":{"id":"1125593879","kind":"news","pubTimestamp":1638756575,"share":"https://www.laohu8.com/m/news/1125593879?lang=zh_CN&edition=full","pubTime":"2021-12-06 10:09","market":"us","language":"en","title":"Why Moderna Is the Biggest Winner From COVID Boosters So Far<blockquote>为什么Moderna是迄今为止COVID加强剂的最大赢家</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125593879","media":"Motley Fool","summary":"It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authoriz","content":"<p>It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authorized boosters for the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) for certain groups. Around two and half months ago, the agency granted authorizations for boosters for Moderna's (NASDAQ:MRNA) and Johnson &amp; Johnson's (NYSE:JNJ) vaccines, with limitations for which individuals could receive the Moderna booster.</p><p><blockquote>美国已经过去大约三个半月了。美国食品和药物管理局(FDA)授权辉瑞(NYSE：PFE)和BioNTech(纳斯达克：BNTX)为某些群体开发的COVID-19疫苗加强剂。大约两个半月前，该机构批准了Moderna（纳斯达克股票代码：MRNA）和强生公司（纽约证券交易所股票代码：JNJ）疫苗的加强剂，但对个人接受Moderna加强剂的范围有所限制。</blockquote></p><p> A little over two weeks ago, the FDA broadened its Emergency Use Authorization for the Pfizer-BioNTech and Moderna boosters to include all adults ages 18 and older. Overall, close to 42 million Americans have received booster shots.</p><p><blockquote>两周多前，FDA扩大了辉瑞-BioNTech和Moderna增强剂的紧急使用授权，将所有18岁及以上的成年人纳入其中。总体而言，近4200万美国人接受了加强注射。</blockquote></p><p> Which vaccine maker is winning the battle of the boosters so far? It's still early, but Moderna appears to be ahead in several respects</p><p><blockquote>到目前为止，哪家疫苗制造商正在赢得加强剂之战？现在还为时过早，但Moderna似乎在几个方面领先</blockquote></p><p> <b>Analyzing the data</b></p><p><blockquote><b>分析数据</b></blockquote></p><p> More booster doses of the Pfizer-BioNTech vaccine have been given than have been administered for the Moderna and J&amp;J boosters. Pfizer and BioNTech are clearly in the lead on this front.</p><p><blockquote>辉瑞-BioNTech疫苗的加强剂量比Moderna和J&amp;J加强剂量还要多。辉瑞和BioNTech在这方面显然处于领先地位。</blockquote></p><p> You'd expect that more people would have received the Pfizer-BioNTech booster. It's been available for many Americans (including those ages 65 and older) for a month longer than the other two vaccine types.</p><p><blockquote>你会认为会有更多的人接受辉瑞-BioNTech加强剂。许多美国人（包括65岁及以上的人）接种疫苗的时间比其他两种疫苗多一个月。</blockquote></p><p> Also, many more individuals received the Pfizer-BioNTech vaccine initially than received the other two vaccines. A lot of those people chose to receive the booster of the same vaccine that they received for their primary series. The chart below shows how the different vaccines stack up against each other based on the fully vaccinated numbers.</p><p><blockquote>此外，最初接受辉瑞-BioNTech疫苗的人比接受其他两种疫苗的人多得多。这些人中的许多人选择接受与他们在初级系列中接受的相同疫苗的加强剂。下图显示了不同疫苗如何根据完全接种的人数相互叠加。</blockquote></p><p> So why do I maintain that Moderna is the biggest winner with boosters so far and not Pfizer or BioNTech? There are three reasons.</p><p><blockquote>那么，为什么我坚持认为Moderna是迄今为止助推器的最大赢家，而不是辉瑞或BioNTech？原因有三。</blockquote></p><p> First, from a financial standpoint, Moderna's 18 million booster doses made it more money than Pfizer or BioNTech made from their 23.3 million or so booster doses. Moderna doesn't have to split its profits as Pfizer and BioNTech do.</p><p><blockquote>首先，从财务角度来看，Moderna的1800万剂加强剂比辉瑞或BioNTech从2330万剂左右的加强剂中赚的钱还要多。Moderna不必像辉瑞和BioNTech那样分配利润。</blockquote></p><p> Second, Moderna is gaining more traction with boosters than Pfizer-BioNTech or J&amp;J are. A little over 25% of the number of fully vaccinated individuals receiving the primary series of the Moderna vaccine have received Moderna boosters. The ratio is 21.3% for Pfizer-BioNTech.</p><p><blockquote>其次，与辉瑞-BioNTech或强生相比，Moderna在助推器方面获得了更多的关注。在接受Moderna疫苗初级系列的完全接种者中，略高于25%的人接受了Moderna加强剂。辉瑞-BioNTech的这一比例为21.3%。</blockquote></p><p> Third, with the FDA allowing mix-and-match boosters, more people appear to be switching from another vaccine to Moderna than they are to any other vaccine type. For those who initially received the J&amp;J vaccine, 42.5% so far have gone with the Moderna booster versus 31.2% for a Pfizer-BioNTech booster and only 26.2% for a J&amp;J booster.</p><p><blockquote>第三，随着FDA允许混合搭配加强剂，从另一种疫苗转向Moderna的人似乎比转向任何其他疫苗类型的人都多。对于最初接种强生疫苗的人来说，迄今为止，42.5%的人接种了Moderna加强剂，而辉瑞-BioNTech加强剂的比例为31.2%，强生加强剂的比例仅为26.2%。</blockquote></p><p> <b>Why is Moderna winning?</b></p><p><blockquote><b>为什么Moderna会赢？</b></blockquote></p><p> We don't know for sure why Moderna seems to be gaining momentum. However, I have a theory for why it could be happening.</p><p><blockquote>我们不确定为什么Moderna似乎正在获得动力。然而，我有一个理论来解释为什么会发生这种情况。</blockquote></p><p> My hunch is that many Americans have heard that Moderna's efficacy against the delta variant is higher than the efficacy of the Pfizer-BioNTech and Johnson &amp; Johnson vaccines. The initial efficacy of the single-shot J&amp;J vaccine was well below its two messenger RNA vaccine rivals. And the efficacy of the Pfizer-BioNTech vaccine appears to have waned more than the Moderna vaccine has with the rise of the delta variant.</p><p><blockquote>我的预感是，许多美国人听说Moderna对德尔塔变异毒株的疗效高于辉瑞-BioNTech和强生疫苗的疗效。单针强生疫苗的初始效力远低于其两种信使RNA疫苗竞争对手。随着德尔塔变异毒株的崛起，辉瑞-BioNTech疫苗的效力似乎比Moderna疫苗减弱得更多。</blockquote></p><p> I suspect that preliminary data showing that a mix-and-match combination of the Pfizer-BioNTech primary series and a Moderna booster provides a higher efficacy could also be making a difference to some extent. Singapore's minister of health even recently recommended that citizens in the country who initially received the Pfizer-BioNTech vaccine get the Moderna booster.</p><p><blockquote>我怀疑初步数据显示，辉瑞-BioNTech primary系列和Moderna booster的混搭组合提供了更高的疗效，这也可能在某种程度上产生影响。新加坡卫生部长最近甚至建议该国最初接种辉瑞-BioNTech疫苗的公民接种Moderna加强剂。</blockquote></p><p> <b>What really matters</b></p><p><blockquote><b>真正重要的是什么</b></blockquote></p><p> Don't expect Moderna's relative outperformance in boosters to do much for the vaccine stock. Many investors aren't paying attention to the data. And the U.S. has already purchased enough doses from Moderna to meet the demand, including boosters.</p><p><blockquote>不要指望Moderna在加强剂方面的相对优异表现会对疫苗股产生多大影响。许多投资者没有关注这些数据。美国已经从Moderna购买了足够的剂量来满足需求，包括加强剂。</blockquote></p><p> What really matters for Moderna is how strong the longer-term demand will be for its COVID-19 vaccine. The company's efforts fighting the new omicron variant could play a key role in shaping that demand. But the most important factors will be whether or not annual vaccines are required to prevent COVID-19 and, if so, what price Moderna will be able to charge.</p><p><blockquote>对Moderna来说，真正重要的是对其COVID-19疫苗的长期需求有多强劲。该公司对抗新奥密克戎变种的努力可能在塑造这一需求方面发挥关键作用。但最重要的因素将是是否需要每年接种疫苗来预防COVID-19，如果需要，Moderna将能够收取什么价格。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Is the Biggest Winner From COVID Boosters So Far<blockquote>为什么Moderna是迄今为止COVID加强剂的最大赢家</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Is the Biggest Winner From COVID Boosters So Far<blockquote>为什么Moderna是迄今为止COVID加强剂的最大赢家</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-12-06 10:09</span>\n</p>\n</h4>\n</header>\n<article>\n<p>It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authorized boosters for the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) for certain groups. Around two and half months ago, the agency granted authorizations for boosters for Moderna's (NASDAQ:MRNA) and Johnson &amp; Johnson's (NYSE:JNJ) vaccines, with limitations for which individuals could receive the Moderna booster.</p><p><blockquote>美国已经过去大约三个半月了。美国食品和药物管理局(FDA)授权辉瑞(NYSE：PFE)和BioNTech(纳斯达克：BNTX)为某些群体开发的COVID-19疫苗加强剂。大约两个半月前，该机构批准了Moderna（纳斯达克股票代码：MRNA）和强生公司（纽约证券交易所股票代码：JNJ）疫苗的加强剂，但对个人接受Moderna加强剂的范围有所限制。</blockquote></p><p> A little over two weeks ago, the FDA broadened its Emergency Use Authorization for the Pfizer-BioNTech and Moderna boosters to include all adults ages 18 and older. Overall, close to 42 million Americans have received booster shots.</p><p><blockquote>两周多前，FDA扩大了辉瑞-BioNTech和Moderna增强剂的紧急使用授权，将所有18岁及以上的成年人纳入其中。总体而言，近4200万美国人接受了加强注射。</blockquote></p><p> Which vaccine maker is winning the battle of the boosters so far? It's still early, but Moderna appears to be ahead in several respects</p><p><blockquote>到目前为止，哪家疫苗制造商正在赢得加强剂之战？现在还为时过早，但Moderna似乎在几个方面领先</blockquote></p><p> <b>Analyzing the data</b></p><p><blockquote><b>分析数据</b></blockquote></p><p> More booster doses of the Pfizer-BioNTech vaccine have been given than have been administered for the Moderna and J&amp;J boosters. Pfizer and BioNTech are clearly in the lead on this front.</p><p><blockquote>辉瑞-BioNTech疫苗的加强剂量比Moderna和J&amp;J加强剂量还要多。辉瑞和BioNTech在这方面显然处于领先地位。</blockquote></p><p> You'd expect that more people would have received the Pfizer-BioNTech booster. It's been available for many Americans (including those ages 65 and older) for a month longer than the other two vaccine types.</p><p><blockquote>你会认为会有更多的人接受辉瑞-BioNTech加强剂。许多美国人（包括65岁及以上的人）接种疫苗的时间比其他两种疫苗多一个月。</blockquote></p><p> Also, many more individuals received the Pfizer-BioNTech vaccine initially than received the other two vaccines. A lot of those people chose to receive the booster of the same vaccine that they received for their primary series. The chart below shows how the different vaccines stack up against each other based on the fully vaccinated numbers.</p><p><blockquote>此外，最初接受辉瑞-BioNTech疫苗的人比接受其他两种疫苗的人多得多。这些人中的许多人选择接受与他们在初级系列中接受的相同疫苗的加强剂。下图显示了不同疫苗如何根据完全接种的人数相互叠加。</blockquote></p><p> So why do I maintain that Moderna is the biggest winner with boosters so far and not Pfizer or BioNTech? There are three reasons.</p><p><blockquote>那么，为什么我坚持认为Moderna是迄今为止助推器的最大赢家，而不是辉瑞或BioNTech？原因有三。</blockquote></p><p> First, from a financial standpoint, Moderna's 18 million booster doses made it more money than Pfizer or BioNTech made from their 23.3 million or so booster doses. Moderna doesn't have to split its profits as Pfizer and BioNTech do.</p><p><blockquote>首先，从财务角度来看，Moderna的1800万剂加强剂比辉瑞或BioNTech从2330万剂左右的加强剂中赚的钱还要多。Moderna不必像辉瑞和BioNTech那样分配利润。</blockquote></p><p> Second, Moderna is gaining more traction with boosters than Pfizer-BioNTech or J&amp;J are. A little over 25% of the number of fully vaccinated individuals receiving the primary series of the Moderna vaccine have received Moderna boosters. The ratio is 21.3% for Pfizer-BioNTech.</p><p><blockquote>其次，与辉瑞-BioNTech或强生相比，Moderna在助推器方面获得了更多的关注。在接受Moderna疫苗初级系列的完全接种者中，略高于25%的人接受了Moderna加强剂。辉瑞-BioNTech的这一比例为21.3%。</blockquote></p><p> Third, with the FDA allowing mix-and-match boosters, more people appear to be switching from another vaccine to Moderna than they are to any other vaccine type. For those who initially received the J&amp;J vaccine, 42.5% so far have gone with the Moderna booster versus 31.2% for a Pfizer-BioNTech booster and only 26.2% for a J&amp;J booster.</p><p><blockquote>第三，随着FDA允许混合搭配加强剂，从另一种疫苗转向Moderna的人似乎比转向任何其他疫苗类型的人都多。对于最初接种强生疫苗的人来说，迄今为止，42.5%的人接种了Moderna加强剂，而辉瑞-BioNTech加强剂的比例为31.2%，强生加强剂的比例仅为26.2%。</blockquote></p><p> <b>Why is Moderna winning?</b></p><p><blockquote><b>为什么Moderna会赢？</b></blockquote></p><p> We don't know for sure why Moderna seems to be gaining momentum. However, I have a theory for why it could be happening.</p><p><blockquote>我们不确定为什么Moderna似乎正在获得动力。然而，我有一个理论来解释为什么会发生这种情况。</blockquote></p><p> My hunch is that many Americans have heard that Moderna's efficacy against the delta variant is higher than the efficacy of the Pfizer-BioNTech and Johnson &amp; Johnson vaccines. The initial efficacy of the single-shot J&amp;J vaccine was well below its two messenger RNA vaccine rivals. And the efficacy of the Pfizer-BioNTech vaccine appears to have waned more than the Moderna vaccine has with the rise of the delta variant.</p><p><blockquote>我的预感是，许多美国人听说Moderna对德尔塔变异毒株的疗效高于辉瑞-BioNTech和强生疫苗的疗效。单针强生疫苗的初始效力远低于其两种信使RNA疫苗竞争对手。随着德尔塔变异毒株的崛起，辉瑞-BioNTech疫苗的效力似乎比Moderna疫苗减弱得更多。</blockquote></p><p> I suspect that preliminary data showing that a mix-and-match combination of the Pfizer-BioNTech primary series and a Moderna booster provides a higher efficacy could also be making a difference to some extent. Singapore's minister of health even recently recommended that citizens in the country who initially received the Pfizer-BioNTech vaccine get the Moderna booster.</p><p><blockquote>我怀疑初步数据显示，辉瑞-BioNTech primary系列和Moderna booster的混搭组合提供了更高的疗效，这也可能在某种程度上产生影响。新加坡卫生部长最近甚至建议该国最初接种辉瑞-BioNTech疫苗的公民接种Moderna加强剂。</blockquote></p><p> <b>What really matters</b></p><p><blockquote><b>真正重要的是什么</b></blockquote></p><p> Don't expect Moderna's relative outperformance in boosters to do much for the vaccine stock. Many investors aren't paying attention to the data. And the U.S. has already purchased enough doses from Moderna to meet the demand, including boosters.</p><p><blockquote>不要指望Moderna在加强剂方面的相对优异表现会对疫苗股产生多大影响。许多投资者没有关注这些数据。美国已经从Moderna购买了足够的剂量来满足需求，包括加强剂。</blockquote></p><p> What really matters for Moderna is how strong the longer-term demand will be for its COVID-19 vaccine. The company's efforts fighting the new omicron variant could play a key role in shaping that demand. But the most important factors will be whether or not annual vaccines are required to prevent COVID-19 and, if so, what price Moderna will be able to charge.</p><p><blockquote>对Moderna来说，真正重要的是对其COVID-19疫苗的长期需求有多强劲。该公司对抗新奥密克戎变种的努力可能在塑造这一需求方面发挥关键作用。但最重要的因素将是是否需要每年接种疫苗来预防COVID-19，如果需要，Moderna将能够收取什么价格。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/12/05/why-moderna-is-the-biggest-winner-from-covid-boost/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/12/05/why-moderna-is-the-biggest-winner-from-covid-boost/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125593879","content_text":"It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authorized boosters for the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) for certain groups. Around two and half months ago, the agency granted authorizations for boosters for Moderna's (NASDAQ:MRNA) and Johnson & Johnson's (NYSE:JNJ) vaccines, with limitations for which individuals could receive the Moderna booster.\n\nA little over two weeks ago, the FDA broadened its Emergency Use Authorization for the Pfizer-BioNTech and Moderna boosters to include all adults ages 18 and older. Overall, close to 42 million Americans have received booster shots.\n\nWhich vaccine maker is winning the battle of the boosters so far? It's still early, but Moderna appears to be ahead in several respects\nAnalyzing the data\nMore booster doses of the Pfizer-BioNTech vaccine have been given than have been administered for the Moderna and J&J boosters. Pfizer and BioNTech are clearly in the lead on this front.\n\nYou'd expect that more people would have received the Pfizer-BioNTech booster. It's been available for many Americans (including those ages 65 and older) for a month longer than the other two vaccine types.\n\nAlso, many more individuals received the Pfizer-BioNTech vaccine initially than received the other two vaccines. A lot of those people chose to receive the booster of the same vaccine that they received for their primary series. The chart below shows how the different vaccines stack up against each other based on the fully vaccinated numbers.\n\nSo why do I maintain that Moderna is the biggest winner with boosters so far and not Pfizer or BioNTech? There are three reasons.\n\nFirst, from a financial standpoint, Moderna's 18 million booster doses made it more money than Pfizer or BioNTech made from their 23.3 million or so booster doses. Moderna doesn't have to split its profits as Pfizer and BioNTech do.\n\nSecond, Moderna is gaining more traction with boosters than Pfizer-BioNTech or J&J are. A little over 25% of the number of fully vaccinated individuals receiving the primary series of the Moderna vaccine have received Moderna boosters. The ratio is 21.3% for Pfizer-BioNTech.\n\nThird, with the FDA allowing mix-and-match boosters, more people appear to be switching from another vaccine to Moderna than they are to any other vaccine type. For those who initially received the J&J vaccine, 42.5% so far have gone with the Moderna booster versus 31.2% for a Pfizer-BioNTech booster and only 26.2% for a J&J booster.\n\nWhy is Moderna winning?\nWe don't know for sure why Moderna seems to be gaining momentum. However, I have a theory for why it could be happening.\n\nMy hunch is that many Americans have heard that Moderna's efficacy against the delta variant is higher than the efficacy of the Pfizer-BioNTech and Johnson & Johnson vaccines. The initial efficacy of the single-shot J&J vaccine was well below its two messenger RNA vaccine rivals. And the efficacy of the Pfizer-BioNTech vaccine appears to have waned more than the Moderna vaccine has with the rise of the delta variant.\n\nI suspect that preliminary data showing that a mix-and-match combination of the Pfizer-BioNTech primary series and a Moderna booster provides a higher efficacy could also be making a difference to some extent. Singapore's minister of health even recently recommended that citizens in the country who initially received the Pfizer-BioNTech vaccine get the Moderna booster.\n\nWhat really matters\nDon't expect Moderna's relative outperformance in boosters to do much for the vaccine stock. Many investors aren't paying attention to the data. And the U.S. has already purchased enough doses from Moderna to meet the demand, including boosters.\n\nWhat really matters for Moderna is how strong the longer-term demand will be for its COVID-19 vaccine. The company's efforts fighting the new omicron variant could play a key role in shaping that demand. But the most important factors will be whether or not annual vaccines are required to prevent COVID-19 and, if so, what price Moderna will be able to charge.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":3121,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":898497158,"gmtCreate":1628516416674,"gmtModify":1631889789540,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Like &amp; comment, please………👆🏻🙏🏻","listText":"Like &amp; comment, please………👆🏻🙏🏻","text":"Like & comment, please………👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/898497158","repostId":"2158238441","repostType":4,"repost":{"id":"2158238441","kind":"highlight","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1628514928,"share":"https://www.laohu8.com/m/news/2158238441?lang=zh_CN&edition=full","pubTime":"2021-08-09 21:15","market":"us","language":"en","title":"BioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid<blockquote>BioNTech股价因盈利大幅增长而上涨；公司的目光超越了新冠疫情</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2158238441","media":"Investors","summary":"BioNTech stock popped on Monday after reporting adjusted profit of $12.67 a share on $6.24 billion in second-quarter sales.","content":"<p>BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.</p><p><blockquote>BioNTech股价周一上涨，此前这家新冠疫苗制造商公布第二季度销售额为62.4亿美元，调整后每股利润为12.67美元。</blockquote></p><p> Analysts polled by FactSet expected <b>BioNTech</b> to earn $8.87 per share on $3.83 billion in sales.</p><p><blockquote>FactSet调查的分析师预期<b>BioNTech</b>销售额为38.3亿美元，每股收益为8.87美元。</blockquote></p><p> In the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.</p><p><blockquote>去年同期，BioNTech每股亏损45美分，营收为4900万美元。</blockquote></p><p> BioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the <b>Pfizer</b> partner to earn $33.12 a share on $14.68 billion in sales.</p><p><blockquote>BioNTech没有提供全年销售和盈利指引。该公司指出，它已达成协议，将在2021年提供22亿剂新冠疫苗，目前正在研究多种癌症药物。分析师呼吁<b>辉瑞</b>合作伙伴的销售额为146.8亿美元，每股收益为33.12美元。</blockquote></p><p> In premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.</p><p><blockquote>在今天股市的盘前交易中，BioNTech股价上涨5%，接近408.50点。根据IBD Digital的数据，该股的完美相对强度评级为99。就12个月的业绩而言，这使得BioNTech股票在所有公司中排名前1%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid<blockquote>BioNTech股价因盈利大幅增长而上涨；公司的目光超越了新冠疫情</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid<blockquote>BioNTech股价因盈利大幅增长而上涨；公司的目光超越了新冠疫情</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time smaller\">2021-08-09 21:15</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.</p><p><blockquote>BioNTech股价周一上涨，此前这家新冠疫苗制造商公布第二季度销售额为62.4亿美元，调整后每股利润为12.67美元。</blockquote></p><p> Analysts polled by FactSet expected <b>BioNTech</b> to earn $8.87 per share on $3.83 billion in sales.</p><p><blockquote>FactSet调查的分析师预期<b>BioNTech</b>销售额为38.3亿美元，每股收益为8.87美元。</blockquote></p><p> In the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.</p><p><blockquote>去年同期，BioNTech每股亏损45美分，营收为4900万美元。</blockquote></p><p> BioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the <b>Pfizer</b> partner to earn $33.12 a share on $14.68 billion in sales.</p><p><blockquote>BioNTech没有提供全年销售和盈利指引。该公司指出，它已达成协议，将在2021年提供22亿剂新冠疫苗，目前正在研究多种癌症药物。分析师呼吁<b>辉瑞</b>合作伙伴的销售额为146.8亿美元，每股收益为33.12美元。</blockquote></p><p> In premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.</p><p><blockquote>在今天股市的盘前交易中，BioNTech股价上涨5%，接近408.50点。根据IBD Digital的数据，该股的完美相对强度评级为99。就12个月的业绩而言，这使得BioNTech股票在所有公司中排名前1%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158238441","content_text":"BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.\nAnalysts polled by FactSet expected BioNTech to earn $8.87 per share on $3.83 billion in sales.\nIn the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.\nBioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the Pfizer partner to earn $33.12 a share on $14.68 billion in sales.\nIn premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.","news_type":1,"symbols_score_info":{"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":1867,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891650118,"gmtCreate":1628388100434,"gmtModify":1631889789559,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Like &amp; comment, please………👆🏻🙏🏻","listText":"Like &amp; comment, please………👆🏻🙏🏻","text":"Like & comment, please………👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/891650118","repostId":"1180529438","repostType":4,"repost":{"id":"1180529438","kind":"news","pubTimestamp":1628386129,"share":"https://www.laohu8.com/m/news/1180529438?lang=zh_CN&edition=full","pubTime":"2021-08-08 09:28","market":"us","language":"en","title":"SEC Moves First DeFi Unregistered Securities Lawsuit<blockquote>SEC提起首起DeFi未注册证券诉讼</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1180529438","media":"Benzinga","summary":"The United States Securities and Exchange Commission  sued the organization responsible for the development of a decentralized finance  protocol over activities involved with the project for the first time.What Happened: According to a Friday SEC announcement, the agency has sued Cayman Islands-based Blockchain Credit Partners and two of its top executives over allegedly selling unregistered securities through its DeFi Money Market platform from February 2020 to February 2021. The firm purported","content":"<p><div> The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project ...</p><p><blockquote><div>美国证券交易委员会（SEC）就该项目涉及的活动起诉了负责开发分散金融（DeFi）协议的组织...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">网页连接</a></blockquote></p><p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SEC Moves First DeFi Unregistered Securities Lawsuit<blockquote>SEC提起首起DeFi未注册证券诉讼</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSEC Moves First DeFi Unregistered Securities Lawsuit<blockquote>SEC提起首起DeFi未注册证券诉讼</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2021-08-08 09:28</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project ...</p><p><blockquote><div>美国证券交易委员会（SEC）就该项目涉及的活动起诉了负责开发分散金融（DeFi）协议的组织...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">Benzinga</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"source_url":"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180529438","content_text":"The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project for the first time.\nWhat Happened: According to a Friday SEC announcement, the agency has sued Cayman Islands-based Blockchain Credit Partners and two of its top executives over allegedly selling unregistered securities through its DeFi Money Market platform from February 2020 to February 2021. The firm purportedly sold over $30 million worth of two types of tokens that the SEC deemed to be securities that should have been registered as such.\nThe SEC notes that Blockchain Credit Partners founders Gregory Keough and Derek Acree will have to pay fines of $125,000 while the company itself also agreed to pay $12.8 million in disgorgement. The settlement does not indicate an admition or denial the accusations.\nNew Game, Old Rules?\nSEC Enforcement Director Gurbir Grewal explained that \"full and honest disclosure remains the cornerstone of our securities laws — no matter what technologies are used to offer and sell those securities.\" This comment makes it very clear that slapping the DeFi label on a project and hoping to avoid regulation this way works no better than calling it a \"utility token\" prevented falling under the SEC's scrutiny during 2017's initial coin offering craze.\nThe SEC is trying to send the clear rule that the new kind of financial organizations that operate on blockchains have to still play by the old rules that govern traditional finance. At the same time, market onlookers are not sure if the regulator is actually right.\nIn a way, it is a tour de force where the regulator wins every time it has a way to take enforcement action, but these new organizations potentially have a very real way to make enforcement impossible — or at the very least impractical. The only protection against enforcement by the SEC and other regulators is decentralization and the only reason why the SEC was able to act in this case is that a centralized organization such as Blockchain Credit Partners exists.\nWhat's Next:If no company exists and all that there is to a DeFi protocol is a set of smart contracts deployed on a blockchain by a group of anonymous developers scattered around the world there is very little that the SEC can do short of attacking the blockchain itself. This is where the decentralization of the underlying blockchain comes into play: will the regulators for instance be able to force Ethereum's (CRYPTO: ETH) core development team to write an update stopping such a project?\nIf the regulators would actually be able to force the blockchain's developers to write such an update, would node operators and miners or stakers adopt this software or would they refuse to? Such situations will be the real test of the decentralization and reliability of any blockchain that many are waiting to happen. Regulators are seeing power slipping away between their fingers like sand, and they are going to try to grab it.","news_type":1,"symbols_score_info":{"COIN":0.9}},"isVote":1,"tweetType":1,"viewCount":1680,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802510374,"gmtCreate":1627787223898,"gmtModify":1631889789570,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Please like and comment 🙏🏻","listText":"Please like and comment 🙏🏻","text":"Please like and comment 🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/802510374","repostId":"1159296868","repostType":4,"isVote":1,"tweetType":1,"viewCount":1770,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802534082,"gmtCreate":1627787044146,"gmtModify":1631889789579,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Like &amp; comment, please………….👆🏻🙏🏻","listText":"Like &amp; comment, please………….👆🏻🙏🏻","text":"Like & comment, please………….👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/802534082","repostId":"2155001152","repostType":4,"isVote":1,"tweetType":1,"viewCount":1732,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802379206,"gmtCreate":1627725322505,"gmtModify":1631889789594,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Please like ……….………………….👆🏻🙏🏻","listText":"Please like ……….………………….👆🏻🙏🏻","text":"Please like ……….………………….👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/802379206","repostId":"2155001152","repostType":4,"isVote":1,"tweetType":1,"viewCount":2116,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164051645,"gmtCreate":1624162333087,"gmtModify":1631889789608,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"🙏🏻🙏🏻🙏🏻","listText":"🙏🏻🙏🏻🙏🏻","text":"🙏🏻🙏🏻🙏🏻","images":[{"img":"https://static.tigerbbs.com/d8dd96436bea0b9c92dd95ae16e70361","width":"1125","height":"1074"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164051645","isVote":1,"tweetType":1,"viewCount":2044,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":166010936,"gmtCreate":1623985232225,"gmtModify":1631889789623,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Read the safety before flying to the moon 🚀🚀🚀","listText":"Read the safety before flying to the moon 🚀🚀🚀","text":"Read the safety before flying to the moon 🚀🚀🚀","images":[{"img":"https://static.tigerbbs.com/bf7f199d98279f47b434137f93979947","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166010936","isVote":1,"tweetType":1,"viewCount":1470,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":161971406,"gmtCreate":1623902995605,"gmtModify":1631889789642,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"一分一毫 清清楚楚","listText":"一分一毫 清清楚楚","text":"一分一毫 清清楚楚","images":[{"img":"https://static.tigerbbs.com/2df10f85bb15a2fd54fd84fa66c51782","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161971406","isVote":1,"tweetType":1,"viewCount":2241,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":169061156,"gmtCreate":1623809414075,"gmtModify":1631889789654,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Lastly, buy!","listText":"Lastly, buy!","text":"Lastly, buy!","images":[{"img":"https://static.tigerbbs.com/977ef722d3398baaae16beac29e882c8","width":"720","height":"720"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169061156","isVote":1,"tweetType":1,"viewCount":1573,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":185908820,"gmtCreate":1623629234460,"gmtModify":1631889789662,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"🙏🏻🙏🏻🙏🏻","listText":"🙏🏻🙏🏻🙏🏻","text":"🙏🏻🙏🏻🙏🏻","images":[{"img":"https://static.tigerbbs.com/810dfc226dde7db2efc68b3b69c713e8","width":"1125","height":"1100"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185908820","isVote":1,"tweetType":1,"viewCount":700,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":181470501,"gmtCreate":1623409319803,"gmtModify":1631893519110,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"🤨🤨🤨","listText":"🤨🤨🤨","text":"🤨🤨🤨","images":[{"img":"https://static.tigerbbs.com/9eef982044c1a06f12729586b864c505","width":"1125","height":"1285"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/181470501","isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":130445533,"gmtCreate":1621563060522,"gmtModify":1631893519123,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"[Cool]&nbsp;[Cool]&nbsp;[Cool]&nbsp;","listText":"[Cool]&nbsp;[Cool]&nbsp;[Cool]&nbsp;","text":"[Cool] [Cool] [Cool]","images":[{"img":"https://static.tigerbbs.com/2df10f85bb15a2fd54fd84fa66c51782","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/130445533","isVote":1,"tweetType":1,"viewCount":654,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":194793896,"gmtCreate":1621398562015,"gmtModify":1631893519136,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"💭💭💭","listText":"💭💭💭","text":"💭💭💭","images":[{"img":"https://static.tigerbbs.com/1b3ccf6b25ac96098455b733bacbd848","width":"1125","height":"1088"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/194793896","isVote":1,"tweetType":1,"viewCount":637,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":196523017,"gmtCreate":1621077977139,"gmtModify":1631893519150,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"The choice is yours","listText":"The choice is yours","text":"The choice is yours","images":[{"img":"https://static.tigerbbs.com/9a8a9e98db8fbea1332f77480b0b2c81","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/196523017","isVote":1,"tweetType":1,"viewCount":395,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":198862076,"gmtCreate":1620951484695,"gmtModify":1631893519163,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Putting money&nbsp;in a&nbsp;bank or&nbsp;buying the bank shares?","listText":"Putting money&nbsp;in a&nbsp;bank or&nbsp;buying the bank shares?","text":"Putting money in a bank or buying the bank shares?","images":[{"img":"https://static.tigerbbs.com/314825c21655ba8acbb27c7862fd8bac","width":"1125","height":"1070"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/198862076","isVote":1,"tweetType":1,"viewCount":498,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":190589276,"gmtCreate":1620633955095,"gmtModify":1631893519172,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Fun fact","listText":"Fun fact","text":"Fun fact","images":[{"img":"https://static.tigerbbs.com/83b46f142a59c6b2396226c8f3fa469f","width":"1125","height":"602"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/190589276","isVote":1,"tweetType":1,"viewCount":451,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":107405123,"gmtCreate":1620526651362,"gmtModify":1631893519186,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"母亲节快乐 !&nbsp;Happy Mother’s Day !🤎♥️❤️🧡💛💚💙💜🤍","listText":"母亲节快乐 !&nbsp;Happy Mother’s Day !🤎♥️❤️🧡💛💚💙💜🤍","text":"母亲节快乐 ! Happy Mother’s Day !🤎♥️❤️🧡💛💚💙💜🤍","images":[{"img":"https://static.tigerbbs.com/985b573fdaca436c795639ecd2b065c5","width":"1125","height":"1283"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/107405123","isVote":1,"tweetType":1,"viewCount":2288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":105023023,"gmtCreate":1620260353262,"gmtModify":1631893519201,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"😎🥸🤓","listText":"😎🥸🤓","text":"😎🥸🤓","images":[{"img":"https://static.tigerbbs.com/df01411b4c036f7e0ec35d5c2817f27d","width":"1125","height":"1260"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/105023023","isVote":1,"tweetType":1,"viewCount":558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":102897280,"gmtCreate":1620191147440,"gmtModify":1631893519209,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Educated&nbsp;them for what they are not learning in school","listText":"Educated&nbsp;them for what they are not learning in school","text":"Educated them for what they are not learning in school","images":[{"img":"https://static.tigerbbs.com/9ffffddc61e04d0a9b36583a41f7c78d","width":"1125","height":"1110"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/102897280","isVote":1,"tweetType":1,"viewCount":305,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":373744064,"gmtCreate":1618887249158,"gmtModify":1634290127183,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Comment and like, pls.","listText":"Comment and like, pls.","text":"Comment and like, pls.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/373744064","repostId":"2128689062","repostType":4,"isVote":1,"tweetType":1,"viewCount":304,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898497158,"gmtCreate":1628516416674,"gmtModify":1631889789540,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Like &amp; comment, please………👆🏻🙏🏻","listText":"Like &amp; comment, please………👆🏻🙏🏻","text":"Like & comment, please………👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/898497158","repostId":"2158238441","repostType":4,"repost":{"id":"2158238441","kind":"highlight","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1628514928,"share":"https://www.laohu8.com/m/news/2158238441?lang=zh_CN&edition=full","pubTime":"2021-08-09 21:15","market":"us","language":"en","title":"BioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid<blockquote>BioNTech股价因盈利大幅增长而上涨；公司的目光超越了新冠疫情</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2158238441","media":"Investors","summary":"BioNTech stock popped on Monday after reporting adjusted profit of $12.67 a share on $6.24 billion in second-quarter sales.","content":"<p>BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.</p><p><blockquote>BioNTech股价周一上涨，此前这家新冠疫苗制造商公布第二季度销售额为62.4亿美元，调整后每股利润为12.67美元。</blockquote></p><p> Analysts polled by FactSet expected <b>BioNTech</b> to earn $8.87 per share on $3.83 billion in sales.</p><p><blockquote>FactSet调查的分析师预期<b>BioNTech</b>销售额为38.3亿美元，每股收益为8.87美元。</blockquote></p><p> In the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.</p><p><blockquote>去年同期，BioNTech每股亏损45美分，营收为4900万美元。</blockquote></p><p> BioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the <b>Pfizer</b> partner to earn $33.12 a share on $14.68 billion in sales.</p><p><blockquote>BioNTech没有提供全年销售和盈利指引。该公司指出，它已达成协议，将在2021年提供22亿剂新冠疫苗，目前正在研究多种癌症药物。分析师呼吁<b>辉瑞</b>合作伙伴的销售额为146.8亿美元，每股收益为33.12美元。</blockquote></p><p> In premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.</p><p><blockquote>在今天股市的盘前交易中，BioNTech股价上涨5%，接近408.50点。根据IBD Digital的数据，该股的完美相对强度评级为99。就12个月的业绩而言，这使得BioNTech股票在所有公司中排名前1%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid<blockquote>BioNTech股价因盈利大幅增长而上涨；公司的目光超越了新冠疫情</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech Stock Pops On Massive Earnings Beat; Company Looks Beyond Covid<blockquote>BioNTech股价因盈利大幅增长而上涨；公司的目光超越了新冠疫情</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time smaller\">2021-08-09 21:15</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.</p><p><blockquote>BioNTech股价周一上涨，此前这家新冠疫苗制造商公布第二季度销售额为62.4亿美元，调整后每股利润为12.67美元。</blockquote></p><p> Analysts polled by FactSet expected <b>BioNTech</b> to earn $8.87 per share on $3.83 billion in sales.</p><p><blockquote>FactSet调查的分析师预期<b>BioNTech</b>销售额为38.3亿美元，每股收益为8.87美元。</blockquote></p><p> In the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.</p><p><blockquote>去年同期，BioNTech每股亏损45美分，营收为4900万美元。</blockquote></p><p> BioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the <b>Pfizer</b> partner to earn $33.12 a share on $14.68 billion in sales.</p><p><blockquote>BioNTech没有提供全年销售和盈利指引。该公司指出，它已达成协议，将在2021年提供22亿剂新冠疫苗，目前正在研究多种癌症药物。分析师呼吁<b>辉瑞</b>合作伙伴的销售额为146.8亿美元，每股收益为33.12美元。</blockquote></p><p> In premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.</p><p><blockquote>在今天股市的盘前交易中，BioNTech股价上涨5%，接近408.50点。根据IBD Digital的数据，该股的完美相对强度评级为99。就12个月的业绩而言，这使得BioNTech股票在所有公司中排名前1%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158238441","content_text":"BioNTech stock popped on Monday after the Covid vaccine maker reported adjusted profit of $12.67 per share on $6.24 billion in second-quarter sales.\nAnalysts polled by FactSet expected BioNTech to earn $8.87 per share on $3.83 billion in sales.\nIn the year-earlier period, BioNTech lost 45 cents per share and reported $49 million in revenue.\nBioNTech didn't offer full-year sales and earnings guidance. The company noted it has agreements in place to deliver 2.2 billion doses of its Covid vaccine in 2021, and is now working on multiple cancer drugs. Analysts called for the Pfizer partner to earn $33.12 a share on $14.68 billion in sales.\nIn premarket trading on today's stock market, BioNTech stock jumped 5% near 408.50. Shares have a perfect Relative Strength Rating of 99, according to IBD Digital. This puts BioNTech stock in the top 1% of all companies in terms of 12-month performance.","news_type":1,"symbols_score_info":{"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":1867,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802534082,"gmtCreate":1627787044146,"gmtModify":1631889789579,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Like &amp; comment, please………….👆🏻🙏🏻","listText":"Like &amp; comment, please………….👆🏻🙏🏻","text":"Like & comment, please………….👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/802534082","repostId":"2155001152","repostType":4,"isVote":1,"tweetType":1,"viewCount":1732,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802379206,"gmtCreate":1627725322505,"gmtModify":1631889789594,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Please like ……….………………….👆🏻🙏🏻","listText":"Please like ……….………………….👆🏻🙏🏻","text":"Please like ……….………………….👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/802379206","repostId":"2155001152","repostType":4,"isVote":1,"tweetType":1,"viewCount":2116,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":375007723,"gmtCreate":1619252337662,"gmtModify":1631893519229,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/375007723","repostId":"1180713929","repostType":4,"repost":{"id":"1180713929","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1619191972,"share":"https://www.laohu8.com/m/news/1180713929?lang=zh_CN&edition=full","pubTime":"2021-04-23 23:32","market":"us","language":"en","title":"Why AMD Stock Popped After Intel's Earnings Beat<blockquote>为什么英特尔盈利超出预期后AMD股价上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1180713929","media":"Tiger Newspress","summary":"Here's a hint: It's not because Intel reported great news.What happenedShares of rising Intel (NASDA","content":"<p>Here's a hint: It's not because Intel reported great news.</p><p><blockquote>这里有一个提示：这并不是因为英特尔报道了好消息。</blockquote></p><p><b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p>Shares of rising&nbsp;<b>Intel</b>&nbsp;(NASDAQ:INTC)&nbsp;rival and fellow&nbsp;semiconductors&nbsp;giant&nbsp;<b>Advanced Micro Devices</b>&nbsp;(NASDAQ:AMD)&nbsp;popped in early trading on the Nasdaq Friday, the first day afterIntel's disappointing Q1 2021 earnings report. AMD's shares were up 4.5% as of 11:30 a.m. EDT.</p><p><blockquote>瑞星股份<b>英特尔</b>（纳斯达克：INTC）竞争对手和半导体巨头<b>先进微设备公司</b>（纳斯达克：AMD）周五在纳斯达克早盘交易中上涨，这是英特尔发布令人失望的2021年第一季度收益报告的第一天。截至美国东部时间上午11:30，AMD股价上涨4.5%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/368e9bc79febd0164dab4a88ffd13c42\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/cf04377bf945cfdaa9a52157bb5560f7\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p><b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p>Intel, if you haven't heard, actually&nbsp;beat&nbsp;on its Q1 earnings. Despite sales declining 1% year over year, the company managed to report a pro forma profit of $1.39 per share, which was ahead of analyst expectations.</p><p><blockquote>如果您还没有听说过，英特尔第一季度的盈利实际上超出了预期。尽管销售额同比下降1%，但该公司仍报告预计每股利润为1.39美元，超出分析师预期。</blockquote></p><p>Regardless, Intel reported a steep 540 basis point decline in its gross margin to 55.2%, and it saw its operating margin cut nearly in half as the company spent heavily to race to catch up to its rivals in advanced computer chips. Analysts at Citigroup commented yesterday that Intel stock appears to be close to its peak valuation and is likely to decline as investors acclimate to the new environment in which Intel is losing, not gaining, market share.</p><p><blockquote>无论如何，英特尔报告称其毛利率大幅下降540个基点至55.2%，并且由于该公司斥巨资追赶先进计算机芯片领域的竞争对手，其营业利润率几乎减半。花旗集团分析师昨日评论称，英特尔股价似乎已接近其估值峰值，随着投资者适应英特尔正在失去而非获得市场份额的新环境，英特尔股价可能会下跌。</blockquote></p><p>And the reason this is good news for&nbsp;AMD&nbsp;is that, according to Citi at least, it's AMD that's taking that market share away from Intel.</p><p><blockquote>这对AMD来说是个好消息的原因是，至少根据花旗的说法，AMD正在从英特尔手中夺走市场份额。</blockquote></p><p><b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p>So what's an investor to do with all this information?</p><p><blockquote>那么投资者如何处理所有这些信息呢？</blockquote></p><p>At a valuation of just 13.6 times trailing earnings, Intel stock certainly looks like a relative bargain when compared with AMD stock, which trades at 38.4 times earnings. But AMD has acash-rich balance sheet, versus Intel that's carrying $13.5 billion in net debt. And analysts see Intel's earnings growing only 10% annually over the next five years, while AMD is pegged for 29.5% annualized earnings growth, according toS&amp;P Global Market Intelligencedata.</p><p><blockquote>英特尔股票的市盈率仅为13.6倍，与AMD股票的市盈率为38.4倍相比，英特尔股票看起来确实相对便宜。但AMD的资产负债表现金充裕，而英特尔的净债务为135亿美元。根据标准普尔全球市场情报数据，分析师预计英特尔未来五年的盈利年增长率仅为10%，而AMD的年化盈利增长率预计为29.5%。</blockquote></p><p>Intel may&nbsp;look&nbsp;like&nbsp;a value stockright now, but it's AMD that's gotall the momentum.</p><p><blockquote>英特尔现在可能看起来像一只价值股，但拥有所有动力的是AMD。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why AMD Stock Popped After Intel's Earnings Beat<blockquote>为什么英特尔盈利超出预期后AMD股价上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy AMD Stock Popped After Intel's Earnings Beat<blockquote>为什么英特尔盈利超出预期后AMD股价上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-04-23 23:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Here's a hint: It's not because Intel reported great news.</p><p><blockquote>这里有一个提示：这并不是因为英特尔报道了好消息。</blockquote></p><p><b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p>Shares of rising&nbsp;<b>Intel</b>&nbsp;(NASDAQ:INTC)&nbsp;rival and fellow&nbsp;semiconductors&nbsp;giant&nbsp;<b>Advanced Micro Devices</b>&nbsp;(NASDAQ:AMD)&nbsp;popped in early trading on the Nasdaq Friday, the first day afterIntel's disappointing Q1 2021 earnings report. AMD's shares were up 4.5% as of 11:30 a.m. EDT.</p><p><blockquote>瑞星股份<b>英特尔</b>（纳斯达克：INTC）竞争对手和半导体巨头<b>先进微设备公司</b>（纳斯达克：AMD）周五在纳斯达克早盘交易中上涨，这是英特尔发布令人失望的2021年第一季度收益报告的第一天。截至美国东部时间上午11:30，AMD股价上涨4.5%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/368e9bc79febd0164dab4a88ffd13c42\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/cf04377bf945cfdaa9a52157bb5560f7\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p><b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p>Intel, if you haven't heard, actually&nbsp;beat&nbsp;on its Q1 earnings. Despite sales declining 1% year over year, the company managed to report a pro forma profit of $1.39 per share, which was ahead of analyst expectations.</p><p><blockquote>如果您还没有听说过，英特尔第一季度的盈利实际上超出了预期。尽管销售额同比下降1%，但该公司仍报告预计每股利润为1.39美元，超出分析师预期。</blockquote></p><p>Regardless, Intel reported a steep 540 basis point decline in its gross margin to 55.2%, and it saw its operating margin cut nearly in half as the company spent heavily to race to catch up to its rivals in advanced computer chips. Analysts at Citigroup commented yesterday that Intel stock appears to be close to its peak valuation and is likely to decline as investors acclimate to the new environment in which Intel is losing, not gaining, market share.</p><p><blockquote>无论如何，英特尔报告称其毛利率大幅下降540个基点至55.2%，并且由于该公司斥巨资追赶先进计算机芯片领域的竞争对手，其营业利润率几乎减半。花旗集团分析师昨日评论称，英特尔股价似乎已接近其估值峰值，随着投资者适应英特尔正在失去而非获得市场份额的新环境，英特尔股价可能会下跌。</blockquote></p><p>And the reason this is good news for&nbsp;AMD&nbsp;is that, according to Citi at least, it's AMD that's taking that market share away from Intel.</p><p><blockquote>这对AMD来说是个好消息的原因是，至少根据花旗的说法，AMD正在从英特尔手中夺走市场份额。</blockquote></p><p><b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p>So what's an investor to do with all this information?</p><p><blockquote>那么投资者如何处理所有这些信息呢？</blockquote></p><p>At a valuation of just 13.6 times trailing earnings, Intel stock certainly looks like a relative bargain when compared with AMD stock, which trades at 38.4 times earnings. But AMD has acash-rich balance sheet, versus Intel that's carrying $13.5 billion in net debt. And analysts see Intel's earnings growing only 10% annually over the next five years, while AMD is pegged for 29.5% annualized earnings growth, according toS&amp;P Global Market Intelligencedata.</p><p><blockquote>英特尔股票的市盈率仅为13.6倍，与AMD股票的市盈率为38.4倍相比，英特尔股票看起来确实相对便宜。但AMD的资产负债表现金充裕，而英特尔的净债务为135亿美元。根据标准普尔全球市场情报数据，分析师预计英特尔未来五年的盈利年增长率仅为10%，而AMD的年化盈利增长率预计为29.5%。</blockquote></p><p>Intel may&nbsp;look&nbsp;like&nbsp;a value stockright now, but it's AMD that's gotall the momentum.</p><p><blockquote>英特尔现在可能看起来像一只价值股，但拥有所有动力的是AMD。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMD":"美国超微公司","INTC":"英特尔"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180713929","content_text":"Here's a hint: It's not because Intel reported great news.What happenedShares of rising Intel (NASDAQ:INTC) rival and fellow semiconductors giant Advanced Micro Devices (NASDAQ:AMD) popped in early trading on the Nasdaq Friday, the first day afterIntel's disappointing Q1 2021 earnings report. AMD's shares were up 4.5% as of 11:30 a.m. EDT.So whatIntel, if you haven't heard, actually beat on its Q1 earnings. Despite sales declining 1% year over year, the company managed to report a pro forma profit of $1.39 per share, which was ahead of analyst expectations.Regardless, Intel reported a steep 540 basis point decline in its gross margin to 55.2%, and it saw its operating margin cut nearly in half as the company spent heavily to race to catch up to its rivals in advanced computer chips. Analysts at Citigroup commented yesterday that Intel stock appears to be close to its peak valuation and is likely to decline as investors acclimate to the new environment in which Intel is losing, not gaining, market share.And the reason this is good news for AMD is that, according to Citi at least, it's AMD that's taking that market share away from Intel.Now whatSo what's an investor to do with all this information?At a valuation of just 13.6 times trailing earnings, Intel stock certainly looks like a relative bargain when compared with AMD stock, which trades at 38.4 times earnings. But AMD has acash-rich balance sheet, versus Intel that's carrying $13.5 billion in net debt. And analysts see Intel's earnings growing only 10% annually over the next five years, while AMD is pegged for 29.5% annualized earnings growth, according toS&P Global Market Intelligencedata.Intel may look like a value stockright now, but it's AMD that's gotall the momentum.","news_type":1,"symbols_score_info":{"INTC":0.9,"AMD":0.9}},"isVote":1,"tweetType":1,"viewCount":328,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891650118,"gmtCreate":1628388100434,"gmtModify":1631889789559,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Like &amp; comment, please………👆🏻🙏🏻","listText":"Like &amp; comment, please………👆🏻🙏🏻","text":"Like & comment, please………👆🏻🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/891650118","repostId":"1180529438","repostType":4,"repost":{"id":"1180529438","kind":"news","pubTimestamp":1628386129,"share":"https://www.laohu8.com/m/news/1180529438?lang=zh_CN&edition=full","pubTime":"2021-08-08 09:28","market":"us","language":"en","title":"SEC Moves First DeFi Unregistered Securities Lawsuit<blockquote>SEC提起首起DeFi未注册证券诉讼</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1180529438","media":"Benzinga","summary":"The United States Securities and Exchange Commission  sued the organization responsible for the development of a decentralized finance  protocol over activities involved with the project for the first time.What Happened: According to a Friday SEC announcement, the agency has sued Cayman Islands-based Blockchain Credit Partners and two of its top executives over allegedly selling unregistered securities through its DeFi Money Market platform from February 2020 to February 2021. The firm purported","content":"<p><div> The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project ...</p><p><blockquote><div>美国证券交易委员会（SEC）就该项目涉及的活动起诉了负责开发分散金融（DeFi）协议的组织...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">网页连接</a></blockquote></p><p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SEC Moves First DeFi Unregistered Securities Lawsuit<blockquote>SEC提起首起DeFi未注册证券诉讼</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSEC Moves First DeFi Unregistered Securities Lawsuit<blockquote>SEC提起首起DeFi未注册证券诉讼</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2021-08-08 09:28</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project ...</p><p><blockquote><div>美国证券交易委员会（SEC）就该项目涉及的活动起诉了负责开发分散金融（DeFi）协议的组织...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit\">Benzinga</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"source_url":"https://www.benzinga.com/markets/cryptocurrency/21/08/22378359/sec-moves-first-defi-unregistered-securities-lawsuit","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180529438","content_text":"The United States Securities and Exchange Commission (SEC) sued the organization responsible for the development of a decentralized finance (DeFi) protocol over activities involved with the project for the first time.\nWhat Happened: According to a Friday SEC announcement, the agency has sued Cayman Islands-based Blockchain Credit Partners and two of its top executives over allegedly selling unregistered securities through its DeFi Money Market platform from February 2020 to February 2021. The firm purportedly sold over $30 million worth of two types of tokens that the SEC deemed to be securities that should have been registered as such.\nThe SEC notes that Blockchain Credit Partners founders Gregory Keough and Derek Acree will have to pay fines of $125,000 while the company itself also agreed to pay $12.8 million in disgorgement. The settlement does not indicate an admition or denial the accusations.\nNew Game, Old Rules?\nSEC Enforcement Director Gurbir Grewal explained that \"full and honest disclosure remains the cornerstone of our securities laws — no matter what technologies are used to offer and sell those securities.\" This comment makes it very clear that slapping the DeFi label on a project and hoping to avoid regulation this way works no better than calling it a \"utility token\" prevented falling under the SEC's scrutiny during 2017's initial coin offering craze.\nThe SEC is trying to send the clear rule that the new kind of financial organizations that operate on blockchains have to still play by the old rules that govern traditional finance. At the same time, market onlookers are not sure if the regulator is actually right.\nIn a way, it is a tour de force where the regulator wins every time it has a way to take enforcement action, but these new organizations potentially have a very real way to make enforcement impossible — or at the very least impractical. The only protection against enforcement by the SEC and other regulators is decentralization and the only reason why the SEC was able to act in this case is that a centralized organization such as Blockchain Credit Partners exists.\nWhat's Next:If no company exists and all that there is to a DeFi protocol is a set of smart contracts deployed on a blockchain by a group of anonymous developers scattered around the world there is very little that the SEC can do short of attacking the blockchain itself. This is where the decentralization of the underlying blockchain comes into play: will the regulators for instance be able to force Ethereum's (CRYPTO: ETH) core development team to write an update stopping such a project?\nIf the regulators would actually be able to force the blockchain's developers to write such an update, would node operators and miners or stakers adopt this software or would they refuse to? Such situations will be the real test of the decentralization and reliability of any blockchain that many are waiting to happen. Regulators are seeing power slipping away between their fingers like sand, and they are going to try to grab it.","news_type":1,"symbols_score_info":{"COIN":0.9}},"isVote":1,"tweetType":1,"viewCount":1680,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":802510374,"gmtCreate":1627787223898,"gmtModify":1631889789570,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Please like and comment 🙏🏻","listText":"Please like and comment 🙏🏻","text":"Please like and comment 🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/802510374","repostId":"1159296868","repostType":4,"isVote":1,"tweetType":1,"viewCount":1770,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":344773698,"gmtCreate":1618446449514,"gmtModify":1634292911898,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"It’s temporary 🦾","listText":"It’s temporary 🦾","text":"It’s temporary 🦾","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/344773698","repostId":"1189551384","repostType":4,"isVote":1,"tweetType":1,"viewCount":423,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":608534193,"gmtCreate":1638756985400,"gmtModify":1638756985492,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/608534193","repostId":"1125593879","repostType":4,"repost":{"id":"1125593879","kind":"news","pubTimestamp":1638756575,"share":"https://www.laohu8.com/m/news/1125593879?lang=zh_CN&edition=full","pubTime":"2021-12-06 10:09","market":"us","language":"en","title":"Why Moderna Is the Biggest Winner From COVID Boosters So Far<blockquote>为什么Moderna是迄今为止COVID加强剂的最大赢家</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125593879","media":"Motley Fool","summary":"It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authoriz","content":"<p>It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authorized boosters for the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) for certain groups. Around two and half months ago, the agency granted authorizations for boosters for Moderna's (NASDAQ:MRNA) and Johnson &amp; Johnson's (NYSE:JNJ) vaccines, with limitations for which individuals could receive the Moderna booster.</p><p><blockquote>美国已经过去大约三个半月了。美国食品和药物管理局(FDA)授权辉瑞(NYSE：PFE)和BioNTech(纳斯达克：BNTX)为某些群体开发的COVID-19疫苗加强剂。大约两个半月前，该机构批准了Moderna（纳斯达克股票代码：MRNA）和强生公司（纽约证券交易所股票代码：JNJ）疫苗的加强剂，但对个人接受Moderna加强剂的范围有所限制。</blockquote></p><p> A little over two weeks ago, the FDA broadened its Emergency Use Authorization for the Pfizer-BioNTech and Moderna boosters to include all adults ages 18 and older. Overall, close to 42 million Americans have received booster shots.</p><p><blockquote>两周多前，FDA扩大了辉瑞-BioNTech和Moderna增强剂的紧急使用授权，将所有18岁及以上的成年人纳入其中。总体而言，近4200万美国人接受了加强注射。</blockquote></p><p> Which vaccine maker is winning the battle of the boosters so far? It's still early, but Moderna appears to be ahead in several respects</p><p><blockquote>到目前为止，哪家疫苗制造商正在赢得加强剂之战？现在还为时过早，但Moderna似乎在几个方面领先</blockquote></p><p> <b>Analyzing the data</b></p><p><blockquote><b>分析数据</b></blockquote></p><p> More booster doses of the Pfizer-BioNTech vaccine have been given than have been administered for the Moderna and J&amp;J boosters. Pfizer and BioNTech are clearly in the lead on this front.</p><p><blockquote>辉瑞-BioNTech疫苗的加强剂量比Moderna和J&amp;J加强剂量还要多。辉瑞和BioNTech在这方面显然处于领先地位。</blockquote></p><p> You'd expect that more people would have received the Pfizer-BioNTech booster. It's been available for many Americans (including those ages 65 and older) for a month longer than the other two vaccine types.</p><p><blockquote>你会认为会有更多的人接受辉瑞-BioNTech加强剂。许多美国人（包括65岁及以上的人）接种疫苗的时间比其他两种疫苗多一个月。</blockquote></p><p> Also, many more individuals received the Pfizer-BioNTech vaccine initially than received the other two vaccines. A lot of those people chose to receive the booster of the same vaccine that they received for their primary series. The chart below shows how the different vaccines stack up against each other based on the fully vaccinated numbers.</p><p><blockquote>此外，最初接受辉瑞-BioNTech疫苗的人比接受其他两种疫苗的人多得多。这些人中的许多人选择接受与他们在初级系列中接受的相同疫苗的加强剂。下图显示了不同疫苗如何根据完全接种的人数相互叠加。</blockquote></p><p> So why do I maintain that Moderna is the biggest winner with boosters so far and not Pfizer or BioNTech? There are three reasons.</p><p><blockquote>那么，为什么我坚持认为Moderna是迄今为止助推器的最大赢家，而不是辉瑞或BioNTech？原因有三。</blockquote></p><p> First, from a financial standpoint, Moderna's 18 million booster doses made it more money than Pfizer or BioNTech made from their 23.3 million or so booster doses. Moderna doesn't have to split its profits as Pfizer and BioNTech do.</p><p><blockquote>首先，从财务角度来看，Moderna的1800万剂加强剂比辉瑞或BioNTech从2330万剂左右的加强剂中赚的钱还要多。Moderna不必像辉瑞和BioNTech那样分配利润。</blockquote></p><p> Second, Moderna is gaining more traction with boosters than Pfizer-BioNTech or J&amp;J are. A little over 25% of the number of fully vaccinated individuals receiving the primary series of the Moderna vaccine have received Moderna boosters. The ratio is 21.3% for Pfizer-BioNTech.</p><p><blockquote>其次，与辉瑞-BioNTech或强生相比，Moderna在助推器方面获得了更多的关注。在接受Moderna疫苗初级系列的完全接种者中，略高于25%的人接受了Moderna加强剂。辉瑞-BioNTech的这一比例为21.3%。</blockquote></p><p> Third, with the FDA allowing mix-and-match boosters, more people appear to be switching from another vaccine to Moderna than they are to any other vaccine type. For those who initially received the J&amp;J vaccine, 42.5% so far have gone with the Moderna booster versus 31.2% for a Pfizer-BioNTech booster and only 26.2% for a J&amp;J booster.</p><p><blockquote>第三，随着FDA允许混合搭配加强剂，从另一种疫苗转向Moderna的人似乎比转向任何其他疫苗类型的人都多。对于最初接种强生疫苗的人来说，迄今为止，42.5%的人接种了Moderna加强剂，而辉瑞-BioNTech加强剂的比例为31.2%，强生加强剂的比例仅为26.2%。</blockquote></p><p> <b>Why is Moderna winning?</b></p><p><blockquote><b>为什么Moderna会赢？</b></blockquote></p><p> We don't know for sure why Moderna seems to be gaining momentum. However, I have a theory for why it could be happening.</p><p><blockquote>我们不确定为什么Moderna似乎正在获得动力。然而，我有一个理论来解释为什么会发生这种情况。</blockquote></p><p> My hunch is that many Americans have heard that Moderna's efficacy against the delta variant is higher than the efficacy of the Pfizer-BioNTech and Johnson &amp; Johnson vaccines. The initial efficacy of the single-shot J&amp;J vaccine was well below its two messenger RNA vaccine rivals. And the efficacy of the Pfizer-BioNTech vaccine appears to have waned more than the Moderna vaccine has with the rise of the delta variant.</p><p><blockquote>我的预感是，许多美国人听说Moderna对德尔塔变异毒株的疗效高于辉瑞-BioNTech和强生疫苗的疗效。单针强生疫苗的初始效力远低于其两种信使RNA疫苗竞争对手。随着德尔塔变异毒株的崛起，辉瑞-BioNTech疫苗的效力似乎比Moderna疫苗减弱得更多。</blockquote></p><p> I suspect that preliminary data showing that a mix-and-match combination of the Pfizer-BioNTech primary series and a Moderna booster provides a higher efficacy could also be making a difference to some extent. Singapore's minister of health even recently recommended that citizens in the country who initially received the Pfizer-BioNTech vaccine get the Moderna booster.</p><p><blockquote>我怀疑初步数据显示，辉瑞-BioNTech primary系列和Moderna booster的混搭组合提供了更高的疗效，这也可能在某种程度上产生影响。新加坡卫生部长最近甚至建议该国最初接种辉瑞-BioNTech疫苗的公民接种Moderna加强剂。</blockquote></p><p> <b>What really matters</b></p><p><blockquote><b>真正重要的是什么</b></blockquote></p><p> Don't expect Moderna's relative outperformance in boosters to do much for the vaccine stock. Many investors aren't paying attention to the data. And the U.S. has already purchased enough doses from Moderna to meet the demand, including boosters.</p><p><blockquote>不要指望Moderna在加强剂方面的相对优异表现会对疫苗股产生多大影响。许多投资者没有关注这些数据。美国已经从Moderna购买了足够的剂量来满足需求，包括加强剂。</blockquote></p><p> What really matters for Moderna is how strong the longer-term demand will be for its COVID-19 vaccine. The company's efforts fighting the new omicron variant could play a key role in shaping that demand. But the most important factors will be whether or not annual vaccines are required to prevent COVID-19 and, if so, what price Moderna will be able to charge.</p><p><blockquote>对Moderna来说，真正重要的是对其COVID-19疫苗的长期需求有多强劲。该公司对抗新奥密克戎变种的努力可能在塑造这一需求方面发挥关键作用。但最重要的因素将是是否需要每年接种疫苗来预防COVID-19，如果需要，Moderna将能够收取什么价格。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Is the Biggest Winner From COVID Boosters So Far<blockquote>为什么Moderna是迄今为止COVID加强剂的最大赢家</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Is the Biggest Winner From COVID Boosters So Far<blockquote>为什么Moderna是迄今为止COVID加强剂的最大赢家</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-12-06 10:09</span>\n</p>\n</h4>\n</header>\n<article>\n<p>It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authorized boosters for the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) for certain groups. Around two and half months ago, the agency granted authorizations for boosters for Moderna's (NASDAQ:MRNA) and Johnson &amp; Johnson's (NYSE:JNJ) vaccines, with limitations for which individuals could receive the Moderna booster.</p><p><blockquote>美国已经过去大约三个半月了。美国食品和药物管理局(FDA)授权辉瑞(NYSE：PFE)和BioNTech(纳斯达克：BNTX)为某些群体开发的COVID-19疫苗加强剂。大约两个半月前，该机构批准了Moderna（纳斯达克股票代码：MRNA）和强生公司（纽约证券交易所股票代码：JNJ）疫苗的加强剂，但对个人接受Moderna加强剂的范围有所限制。</blockquote></p><p> A little over two weeks ago, the FDA broadened its Emergency Use Authorization for the Pfizer-BioNTech and Moderna boosters to include all adults ages 18 and older. Overall, close to 42 million Americans have received booster shots.</p><p><blockquote>两周多前，FDA扩大了辉瑞-BioNTech和Moderna增强剂的紧急使用授权，将所有18岁及以上的成年人纳入其中。总体而言，近4200万美国人接受了加强注射。</blockquote></p><p> Which vaccine maker is winning the battle of the boosters so far? It's still early, but Moderna appears to be ahead in several respects</p><p><blockquote>到目前为止，哪家疫苗制造商正在赢得加强剂之战？现在还为时过早，但Moderna似乎在几个方面领先</blockquote></p><p> <b>Analyzing the data</b></p><p><blockquote><b>分析数据</b></blockquote></p><p> More booster doses of the Pfizer-BioNTech vaccine have been given than have been administered for the Moderna and J&amp;J boosters. Pfizer and BioNTech are clearly in the lead on this front.</p><p><blockquote>辉瑞-BioNTech疫苗的加强剂量比Moderna和J&amp;J加强剂量还要多。辉瑞和BioNTech在这方面显然处于领先地位。</blockquote></p><p> You'd expect that more people would have received the Pfizer-BioNTech booster. It's been available for many Americans (including those ages 65 and older) for a month longer than the other two vaccine types.</p><p><blockquote>你会认为会有更多的人接受辉瑞-BioNTech加强剂。许多美国人（包括65岁及以上的人）接种疫苗的时间比其他两种疫苗多一个月。</blockquote></p><p> Also, many more individuals received the Pfizer-BioNTech vaccine initially than received the other two vaccines. A lot of those people chose to receive the booster of the same vaccine that they received for their primary series. The chart below shows how the different vaccines stack up against each other based on the fully vaccinated numbers.</p><p><blockquote>此外，最初接受辉瑞-BioNTech疫苗的人比接受其他两种疫苗的人多得多。这些人中的许多人选择接受与他们在初级系列中接受的相同疫苗的加强剂。下图显示了不同疫苗如何根据完全接种的人数相互叠加。</blockquote></p><p> So why do I maintain that Moderna is the biggest winner with boosters so far and not Pfizer or BioNTech? There are three reasons.</p><p><blockquote>那么，为什么我坚持认为Moderna是迄今为止助推器的最大赢家，而不是辉瑞或BioNTech？原因有三。</blockquote></p><p> First, from a financial standpoint, Moderna's 18 million booster doses made it more money than Pfizer or BioNTech made from their 23.3 million or so booster doses. Moderna doesn't have to split its profits as Pfizer and BioNTech do.</p><p><blockquote>首先，从财务角度来看，Moderna的1800万剂加强剂比辉瑞或BioNTech从2330万剂左右的加强剂中赚的钱还要多。Moderna不必像辉瑞和BioNTech那样分配利润。</blockquote></p><p> Second, Moderna is gaining more traction with boosters than Pfizer-BioNTech or J&amp;J are. A little over 25% of the number of fully vaccinated individuals receiving the primary series of the Moderna vaccine have received Moderna boosters. The ratio is 21.3% for Pfizer-BioNTech.</p><p><blockquote>其次，与辉瑞-BioNTech或强生相比，Moderna在助推器方面获得了更多的关注。在接受Moderna疫苗初级系列的完全接种者中，略高于25%的人接受了Moderna加强剂。辉瑞-BioNTech的这一比例为21.3%。</blockquote></p><p> Third, with the FDA allowing mix-and-match boosters, more people appear to be switching from another vaccine to Moderna than they are to any other vaccine type. For those who initially received the J&amp;J vaccine, 42.5% so far have gone with the Moderna booster versus 31.2% for a Pfizer-BioNTech booster and only 26.2% for a J&amp;J booster.</p><p><blockquote>第三，随着FDA允许混合搭配加强剂，从另一种疫苗转向Moderna的人似乎比转向任何其他疫苗类型的人都多。对于最初接种强生疫苗的人来说，迄今为止，42.5%的人接种了Moderna加强剂，而辉瑞-BioNTech加强剂的比例为31.2%，强生加强剂的比例仅为26.2%。</blockquote></p><p> <b>Why is Moderna winning?</b></p><p><blockquote><b>为什么Moderna会赢？</b></blockquote></p><p> We don't know for sure why Moderna seems to be gaining momentum. However, I have a theory for why it could be happening.</p><p><blockquote>我们不确定为什么Moderna似乎正在获得动力。然而，我有一个理论来解释为什么会发生这种情况。</blockquote></p><p> My hunch is that many Americans have heard that Moderna's efficacy against the delta variant is higher than the efficacy of the Pfizer-BioNTech and Johnson &amp; Johnson vaccines. The initial efficacy of the single-shot J&amp;J vaccine was well below its two messenger RNA vaccine rivals. And the efficacy of the Pfizer-BioNTech vaccine appears to have waned more than the Moderna vaccine has with the rise of the delta variant.</p><p><blockquote>我的预感是，许多美国人听说Moderna对德尔塔变异毒株的疗效高于辉瑞-BioNTech和强生疫苗的疗效。单针强生疫苗的初始效力远低于其两种信使RNA疫苗竞争对手。随着德尔塔变异毒株的崛起，辉瑞-BioNTech疫苗的效力似乎比Moderna疫苗减弱得更多。</blockquote></p><p> I suspect that preliminary data showing that a mix-and-match combination of the Pfizer-BioNTech primary series and a Moderna booster provides a higher efficacy could also be making a difference to some extent. Singapore's minister of health even recently recommended that citizens in the country who initially received the Pfizer-BioNTech vaccine get the Moderna booster.</p><p><blockquote>我怀疑初步数据显示，辉瑞-BioNTech primary系列和Moderna booster的混搭组合提供了更高的疗效，这也可能在某种程度上产生影响。新加坡卫生部长最近甚至建议该国最初接种辉瑞-BioNTech疫苗的公民接种Moderna加强剂。</blockquote></p><p> <b>What really matters</b></p><p><blockquote><b>真正重要的是什么</b></blockquote></p><p> Don't expect Moderna's relative outperformance in boosters to do much for the vaccine stock. Many investors aren't paying attention to the data. And the U.S. has already purchased enough doses from Moderna to meet the demand, including boosters.</p><p><blockquote>不要指望Moderna在加强剂方面的相对优异表现会对疫苗股产生多大影响。许多投资者没有关注这些数据。美国已经从Moderna购买了足够的剂量来满足需求，包括加强剂。</blockquote></p><p> What really matters for Moderna is how strong the longer-term demand will be for its COVID-19 vaccine. The company's efforts fighting the new omicron variant could play a key role in shaping that demand. But the most important factors will be whether or not annual vaccines are required to prevent COVID-19 and, if so, what price Moderna will be able to charge.</p><p><blockquote>对Moderna来说，真正重要的是对其COVID-19疫苗的长期需求有多强劲。该公司对抗新奥密克戎变种的努力可能在塑造这一需求方面发挥关键作用。但最重要的因素将是是否需要每年接种疫苗来预防COVID-19，如果需要，Moderna将能够收取什么价格。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/12/05/why-moderna-is-the-biggest-winner-from-covid-boost/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/12/05/why-moderna-is-the-biggest-winner-from-covid-boost/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125593879","content_text":"It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authorized boosters for the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) for certain groups. Around two and half months ago, the agency granted authorizations for boosters for Moderna's (NASDAQ:MRNA) and Johnson & Johnson's (NYSE:JNJ) vaccines, with limitations for which individuals could receive the Moderna booster.\n\nA little over two weeks ago, the FDA broadened its Emergency Use Authorization for the Pfizer-BioNTech and Moderna boosters to include all adults ages 18 and older. Overall, close to 42 million Americans have received booster shots.\n\nWhich vaccine maker is winning the battle of the boosters so far? It's still early, but Moderna appears to be ahead in several respects\nAnalyzing the data\nMore booster doses of the Pfizer-BioNTech vaccine have been given than have been administered for the Moderna and J&J boosters. Pfizer and BioNTech are clearly in the lead on this front.\n\nYou'd expect that more people would have received the Pfizer-BioNTech booster. It's been available for many Americans (including those ages 65 and older) for a month longer than the other two vaccine types.\n\nAlso, many more individuals received the Pfizer-BioNTech vaccine initially than received the other two vaccines. A lot of those people chose to receive the booster of the same vaccine that they received for their primary series. The chart below shows how the different vaccines stack up against each other based on the fully vaccinated numbers.\n\nSo why do I maintain that Moderna is the biggest winner with boosters so far and not Pfizer or BioNTech? There are three reasons.\n\nFirst, from a financial standpoint, Moderna's 18 million booster doses made it more money than Pfizer or BioNTech made from their 23.3 million or so booster doses. Moderna doesn't have to split its profits as Pfizer and BioNTech do.\n\nSecond, Moderna is gaining more traction with boosters than Pfizer-BioNTech or J&J are. A little over 25% of the number of fully vaccinated individuals receiving the primary series of the Moderna vaccine have received Moderna boosters. The ratio is 21.3% for Pfizer-BioNTech.\n\nThird, with the FDA allowing mix-and-match boosters, more people appear to be switching from another vaccine to Moderna than they are to any other vaccine type. For those who initially received the J&J vaccine, 42.5% so far have gone with the Moderna booster versus 31.2% for a Pfizer-BioNTech booster and only 26.2% for a J&J booster.\n\nWhy is Moderna winning?\nWe don't know for sure why Moderna seems to be gaining momentum. However, I have a theory for why it could be happening.\n\nMy hunch is that many Americans have heard that Moderna's efficacy against the delta variant is higher than the efficacy of the Pfizer-BioNTech and Johnson & Johnson vaccines. The initial efficacy of the single-shot J&J vaccine was well below its two messenger RNA vaccine rivals. And the efficacy of the Pfizer-BioNTech vaccine appears to have waned more than the Moderna vaccine has with the rise of the delta variant.\n\nI suspect that preliminary data showing that a mix-and-match combination of the Pfizer-BioNTech primary series and a Moderna booster provides a higher efficacy could also be making a difference to some extent. Singapore's minister of health even recently recommended that citizens in the country who initially received the Pfizer-BioNTech vaccine get the Moderna booster.\n\nWhat really matters\nDon't expect Moderna's relative outperformance in boosters to do much for the vaccine stock. Many investors aren't paying attention to the data. And the U.S. has already purchased enough doses from Moderna to meet the demand, including boosters.\n\nWhat really matters for Moderna is how strong the longer-term demand will be for its COVID-19 vaccine. The company's efforts fighting the new omicron variant could play a key role in shaping that demand. But the most important factors will be whether or not annual vaccines are required to prevent COVID-19 and, if so, what price Moderna will be able to charge.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":3121,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":349868988,"gmtCreate":1617589262544,"gmtModify":1634297709423,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"[得意]&nbsp;[财迷]&nbsp;[笑哭]&nbsp;","listText":"[得意]&nbsp;[财迷]&nbsp;[笑哭]&nbsp;","text":"[得意] [财迷] [笑哭]","images":[{"img":"https://static.tigerbbs.com/dec358618f34345ab53891ca61fd409a","width":"1125","height":"1107"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/349868988","isVote":1,"tweetType":1,"viewCount":1621,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":382396902,"gmtCreate":1613358787706,"gmtModify":1634553867761,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Hope it happens","listText":"Hope it happens","text":"Hope it happens","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/382396902","repostId":"2110204192","repostType":4,"isVote":1,"tweetType":1,"viewCount":503,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":344779970,"gmtCreate":1618446346490,"gmtModify":1634292913070,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Pls help&nbsp;comment and like 🙏🏻","listText":"Pls help&nbsp;comment and like 🙏🏻","text":"Pls help comment and like 🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/344779970","repostId":"1150191459","repostType":4,"isVote":1,"tweetType":1,"viewCount":179,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":327113538,"gmtCreate":1616068912424,"gmtModify":1634527409178,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Way to go!","listText":"Way to go!","text":"Way to go!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/327113538","repostId":"1141211447","repostType":4,"repost":{"id":"1141211447","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1616067847,"share":"https://www.laohu8.com/m/news/1141211447?lang=zh_CN&edition=full","pubTime":"2021-03-18 19:44","market":"us","language":"en","title":"Legend Biotech EPS beats by $0.08, beats on revenue<blockquote>传奇生物EPS超过预期0.08美元，营收超过预期</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1141211447","media":"Tiger Newspress","summary":"(March 18) Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business U","content":"<p>(March 18)&nbsp;Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update.</p><p><blockquote>（3月18日）传奇生物公布2020年第四季度及全年财务业绩及业务更新。</blockquote></p><p> <ul>  <li>Legend Biotech&nbsp;: Q4 GAAP EPS of -$0.22beats by $0.08.</li>  <li>Revenue of $40.78M (+109.7% Y/Y)beats by $28.78M.</li> </ul> <img src=\"https://static.tigerbbs.com/03aed76701fd868589414ae62671e72a\" tg-width=\"685\" tg-height=\"498\"></p><p><blockquote><ul><li>传奇生物：第四季度GAAP每股收益为-0.22美元超过预期为0.08美元。</li><li>收入为4078万美元（同比增长109.7%）超过预期2878万美元。</li></ul></blockquote></p><p> <b>Financial Results for the Quarter and Year Ended December 31, 2020</b></p><p><blockquote><b>截至2020年12月31日的季度和年度财务业绩</b></blockquote></p><p> Cash and Cash Equivalents and time deposits:</p><p><blockquote>现金及现金等价物及定期存款：</blockquote></p><p> As of December 31, 2020, Legend Biotech had approximately $455.7 million of cash and cash equivalents and approximately $50.0 million in time deposits.</p><p><blockquote>截至2020年12月31日，传奇生物拥有约4.557亿美元的现金及现金等价物以及约5000万美元的定期存款。</blockquote></p><p> <b>Revenue</b></p><p><blockquote><b>收入</b></blockquote></p><p> Revenue for the three months ended December 31, 2020 was $40.8 million compared to $19.5 million for the three months ended December 31, 2019. The increase of $21.3 million was primarily due to revenue recognition of additional milestone payment achieved of higher amount pursuant to Legend Biotech’s agreement with Janssen and the associated constrained variable consideration is relieved. Revenue for the year ended December 31, 2020 was $75.7 million compared to $57.3 million for the year ended December 31, 2019. Similarly, the increase of $18.4 million for the year ended December 31, 2020 was primarily driven by revenue recognized from an additional milestone achieved of higher amount. Legend Biotech has not generated any revenue from product sales to date.</p><p><blockquote>截至2020年12月31日的三个月收入为4080万美元，而截至2019年12月31日的三个月为1950万美元。增加2130万美元主要是由于根据传奇生物与杨森的协议实现的更高金额的额外里程碑付款的收入确认以及相关的受限可变对价被解除。截至2020年12月31日止年度的收入为7570万美元，而截至2019年12月31日止年度为5730万美元。同样，截至2020年12月31日的年度增加了1840万美元，主要是由于实现了更高金额的额外里程碑而确认的收入。传奇生物迄今尚未从产品销售中产生任何收入。</blockquote></p><p> <b>Research and Development Expenses</b></p><p><blockquote><b>研发费用</b></blockquote></p><p> Research and development expenses for the three months ended December 31, 2020 were $66.9 million compared to $66.1 million for the three months ended December 31, 2019. This increase of $0.8 million was primarily due to an increase in employee benefit expense and research and development expense, net-off by a decrease in collaborative research and development expenses. Research and development expenses for the year ended December 31, 2020 was $232.2 million compared to $161.9 million for the year ended December 31, 2019 with a $70.3 million increase. The year-over-year increase was primarily due to a higher number of clinical trials, a higher number of patients enrolled in those trials and a higher number of research and development product candidates in the year ended December 31, 2020.</p><p><blockquote>截至2020年12月31日的三个月的研发费用为6690万美元，而截至2019年12月31日的三个月为6610万美元。80万美元的增加主要是由于员工福利费用和研发费用的增加，但被合作研发费用的减少所抵消。截至2020年12月31日止年度的研发费用为2.322亿美元，与截至2019年12月31日止年度的1.619亿美元相比，增加了7030万美元。同比增长主要是由于截至2020年12月31日止年度临床试验数量增加、参加这些试验的患者数量增加以及研发候选产品数量增加。</blockquote></p><p> <b>Loss for the Period</b></p><p><blockquote><b>期内亏损</b></blockquote></p><p> For the three months ended December 31, 2020, net loss was $57.8 million, or $0.22 per share, compared to a net loss of $63.9 million, or $0.32 per share, for the three months ended December 31, 2019. Net loss was $303.5 million, or $1.28 per share, for the year ended December 31, 2020 compared to $133.0 million, or $0.66 per share, for the year ended December 31, 2019.</p><p><blockquote>截至2020年12月31日的三个月，净亏损为5780万美元，或每股0.22美元，而截至2019年12月31日的三个月净亏损为6390万美元，或每股0.32美元。截至2020年12月31日的年度净亏损为3.035亿美元，或每股1.28美元，而截至2019年12月31日的年度净亏损为1.33亿美元，或每股0.66美元。</blockquote></p><p> Key Upcoming Milestones</p><p><blockquote>即将到来的关键里程碑</blockquote></p><p> <ul>  <li>Legend Biotech’s collaborator, Janssen, anticipates submitting a MAA for cilta-cel for the treatment of adults with RRMM to the EMA in the first half of 2021.</li>  <li>Legend Biotech intends to use the data from the CARTIFAN-1 study in support of a regulatory submission to the China Center for Drug Evaluation (CDE) seeking approval of cilta-cel for the treatment of adults with RRMM. Legend Biotech expects the submission of the application to occur in the second half of 2021.</li>  <li>Legend Biotech’s collaborator, Janssen, anticipates submitting a New Drug Application (NDA) to the Japan Ministry of Health, Labor and Welfare (JMHLW) in the second half of 2021 seeking approval of cilta-cel for the treatment of adults with RRMM.</li>  <li>Legend Biotech expects to initiate its Phase 1 clinical trial of LB1901 in RR TCL inthe United Statesin 2021.</li>  <li>Legend Biotech, in collaboration with Janssen, intends to present updated data from the CARTITUDE-1 and data from CARTITUDE-2 studies at major medical conferences in 2021.</li>  <li>Legend Biotech anticipates supporting investigators with publishing a clinical data update from LEGEND-2 study in 2021.</li> </ul> As the global COVID-19 pandemic continues to evolve, Legend Biotech has continuously monitored the situation in regards to its operations and has put significant measures in place to protect supply chain, operations, employees and the execution of clinical trials. Given the dynamic global situation, Legend Biotech notes that certain clinical trial timelines may be impacted.</p><p><blockquote><ul><li>传奇生物的合作者杨森预计将于2021年上半年向EMA提交cilta-cel治疗成人RRMM的MAA。</li><li>传奇生物打算使用CARTIFAN-1研究的数据来支持向中国药品审评中心（CDE）提交的监管文件，寻求批准cilta-cel用于治疗成人RRMM。传奇生物预计将于2021年下半年提交申请。</li><li>传奇生物的合作者杨森预计将于2021年下半年向日本厚生劳动省（JMHLW）提交新药申请（NDA），寻求批准cilta-cel用于治疗成人RRMM。</li><li>传奇生物预计将于2021年在美国启动LB1901在RR TCL的1期临床试验。</li><li>传奇生物与杨森合作，打算在2021年的主要医学会议上展示CARTITUDE-1的最新数据和CARTITUDE-2研究的数据。</li><li>传奇生物预计将于2021年支持研究人员发布LEGEND-2研究的临床数据更新。</li></ul>随著全球COVID-19疫情持续发展，传奇生物持续监控其营运情况，并已采取重大措施保护供应链、营运、僱员及临床试验的执行。鉴于全球形势的动态，传奇生物指出，某些临床试验时间表可能会受到影响。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech EPS beats by $0.08, beats on revenue<blockquote>传奇生物EPS超过预期0.08美元，营收超过预期</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech EPS beats by $0.08, beats on revenue<blockquote>传奇生物EPS超过预期0.08美元，营收超过预期</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-03-18 19:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(March 18)&nbsp;Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update.</p><p><blockquote>（3月18日）传奇生物公布2020年第四季度及全年财务业绩及业务更新。</blockquote></p><p> <ul>  <li>Legend Biotech&nbsp;: Q4 GAAP EPS of -$0.22beats by $0.08.</li>  <li>Revenue of $40.78M (+109.7% Y/Y)beats by $28.78M.</li> </ul> <img src=\"https://static.tigerbbs.com/03aed76701fd868589414ae62671e72a\" tg-width=\"685\" tg-height=\"498\"></p><p><blockquote><ul><li>传奇生物：第四季度GAAP每股收益为-0.22美元超过预期为0.08美元。</li><li>收入为4078万美元（同比增长109.7%）超过预期2878万美元。</li></ul></blockquote></p><p> <b>Financial Results for the Quarter and Year Ended December 31, 2020</b></p><p><blockquote><b>截至2020年12月31日的季度和年度财务业绩</b></blockquote></p><p> Cash and Cash Equivalents and time deposits:</p><p><blockquote>现金及现金等价物及定期存款：</blockquote></p><p> As of December 31, 2020, Legend Biotech had approximately $455.7 million of cash and cash equivalents and approximately $50.0 million in time deposits.</p><p><blockquote>截至2020年12月31日，传奇生物拥有约4.557亿美元的现金及现金等价物以及约5000万美元的定期存款。</blockquote></p><p> <b>Revenue</b></p><p><blockquote><b>收入</b></blockquote></p><p> Revenue for the three months ended December 31, 2020 was $40.8 million compared to $19.5 million for the three months ended December 31, 2019. The increase of $21.3 million was primarily due to revenue recognition of additional milestone payment achieved of higher amount pursuant to Legend Biotech’s agreement with Janssen and the associated constrained variable consideration is relieved. Revenue for the year ended December 31, 2020 was $75.7 million compared to $57.3 million for the year ended December 31, 2019. Similarly, the increase of $18.4 million for the year ended December 31, 2020 was primarily driven by revenue recognized from an additional milestone achieved of higher amount. Legend Biotech has not generated any revenue from product sales to date.</p><p><blockquote>截至2020年12月31日的三个月收入为4080万美元，而截至2019年12月31日的三个月为1950万美元。增加2130万美元主要是由于根据传奇生物与杨森的协议实现的更高金额的额外里程碑付款的收入确认以及相关的受限可变对价被解除。截至2020年12月31日止年度的收入为7570万美元，而截至2019年12月31日止年度为5730万美元。同样，截至2020年12月31日的年度增加了1840万美元，主要是由于实现了更高金额的额外里程碑而确认的收入。传奇生物迄今尚未从产品销售中产生任何收入。</blockquote></p><p> <b>Research and Development Expenses</b></p><p><blockquote><b>研发费用</b></blockquote></p><p> Research and development expenses for the three months ended December 31, 2020 were $66.9 million compared to $66.1 million for the three months ended December 31, 2019. This increase of $0.8 million was primarily due to an increase in employee benefit expense and research and development expense, net-off by a decrease in collaborative research and development expenses. Research and development expenses for the year ended December 31, 2020 was $232.2 million compared to $161.9 million for the year ended December 31, 2019 with a $70.3 million increase. The year-over-year increase was primarily due to a higher number of clinical trials, a higher number of patients enrolled in those trials and a higher number of research and development product candidates in the year ended December 31, 2020.</p><p><blockquote>截至2020年12月31日的三个月的研发费用为6690万美元，而截至2019年12月31日的三个月为6610万美元。80万美元的增加主要是由于员工福利费用和研发费用的增加，但被合作研发费用的减少所抵消。截至2020年12月31日止年度的研发费用为2.322亿美元，与截至2019年12月31日止年度的1.619亿美元相比，增加了7030万美元。同比增长主要是由于截至2020年12月31日止年度临床试验数量增加、参加这些试验的患者数量增加以及研发候选产品数量增加。</blockquote></p><p> <b>Loss for the Period</b></p><p><blockquote><b>期内亏损</b></blockquote></p><p> For the three months ended December 31, 2020, net loss was $57.8 million, or $0.22 per share, compared to a net loss of $63.9 million, or $0.32 per share, for the three months ended December 31, 2019. Net loss was $303.5 million, or $1.28 per share, for the year ended December 31, 2020 compared to $133.0 million, or $0.66 per share, for the year ended December 31, 2019.</p><p><blockquote>截至2020年12月31日的三个月，净亏损为5780万美元，或每股0.22美元，而截至2019年12月31日的三个月净亏损为6390万美元，或每股0.32美元。截至2020年12月31日的年度净亏损为3.035亿美元，或每股1.28美元，而截至2019年12月31日的年度净亏损为1.33亿美元，或每股0.66美元。</blockquote></p><p> Key Upcoming Milestones</p><p><blockquote>即将到来的关键里程碑</blockquote></p><p> <ul>  <li>Legend Biotech’s collaborator, Janssen, anticipates submitting a MAA for cilta-cel for the treatment of adults with RRMM to the EMA in the first half of 2021.</li>  <li>Legend Biotech intends to use the data from the CARTIFAN-1 study in support of a regulatory submission to the China Center for Drug Evaluation (CDE) seeking approval of cilta-cel for the treatment of adults with RRMM. Legend Biotech expects the submission of the application to occur in the second half of 2021.</li>  <li>Legend Biotech’s collaborator, Janssen, anticipates submitting a New Drug Application (NDA) to the Japan Ministry of Health, Labor and Welfare (JMHLW) in the second half of 2021 seeking approval of cilta-cel for the treatment of adults with RRMM.</li>  <li>Legend Biotech expects to initiate its Phase 1 clinical trial of LB1901 in RR TCL inthe United Statesin 2021.</li>  <li>Legend Biotech, in collaboration with Janssen, intends to present updated data from the CARTITUDE-1 and data from CARTITUDE-2 studies at major medical conferences in 2021.</li>  <li>Legend Biotech anticipates supporting investigators with publishing a clinical data update from LEGEND-2 study in 2021.</li> </ul> As the global COVID-19 pandemic continues to evolve, Legend Biotech has continuously monitored the situation in regards to its operations and has put significant measures in place to protect supply chain, operations, employees and the execution of clinical trials. Given the dynamic global situation, Legend Biotech notes that certain clinical trial timelines may be impacted.</p><p><blockquote><ul><li>传奇生物的合作者杨森预计将于2021年上半年向EMA提交cilta-cel治疗成人RRMM的MAA。</li><li>传奇生物打算使用CARTIFAN-1研究的数据来支持向中国药品审评中心（CDE）提交的监管文件，寻求批准cilta-cel用于治疗成人RRMM。传奇生物预计将于2021年下半年提交申请。</li><li>传奇生物的合作者杨森预计将于2021年下半年向日本厚生劳动省（JMHLW）提交新药申请（NDA），寻求批准cilta-cel用于治疗成人RRMM。</li><li>传奇生物预计将于2021年在美国启动LB1901在RR TCL的1期临床试验。</li><li>传奇生物与杨森合作，打算在2021年的主要医学会议上展示CARTITUDE-1的最新数据和CARTITUDE-2研究的数据。</li><li>传奇生物预计将于2021年支持研究人员发布LEGEND-2研究的临床数据更新。</li></ul>随著全球COVID-19疫情持续发展，传奇生物持续监控其营运情况，并已采取重大措施保护供应链、营运、僱员及临床试验的执行。鉴于全球形势的动态，传奇生物指出，某些临床试验时间表可能会受到影响。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LEGN":"传奇生物"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141211447","content_text":"(March 18) Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update.\n\nLegend Biotech : Q4 GAAP EPS of -$0.22beats by $0.08.\nRevenue of $40.78M (+109.7% Y/Y)beats by $28.78M.\n\n\nFinancial Results for the Quarter and Year Ended December 31, 2020\nCash and Cash Equivalents and time deposits:\nAs of December 31, 2020, Legend Biotech had approximately $455.7 million of cash and cash equivalents and approximately $50.0 million in time deposits.\nRevenue\nRevenue for the three months ended December 31, 2020 was $40.8 million compared to $19.5 million for the three months ended December 31, 2019. The increase of $21.3 million was primarily due to revenue recognition of additional milestone payment achieved of higher amount pursuant to Legend Biotech’s agreement with Janssen and the associated constrained variable consideration is relieved. Revenue for the year ended December 31, 2020 was $75.7 million compared to $57.3 million for the year ended December 31, 2019. Similarly, the increase of $18.4 million for the year ended December 31, 2020 was primarily driven by revenue recognized from an additional milestone achieved of higher amount. Legend Biotech has not generated any revenue from product sales to date.\nResearch and Development Expenses\nResearch and development expenses for the three months ended December 31, 2020 were $66.9 million compared to $66.1 million for the three months ended December 31, 2019. This increase of $0.8 million was primarily due to an increase in employee benefit expense and research and development expense, net-off by a decrease in collaborative research and development expenses. Research and development expenses for the year ended December 31, 2020 was $232.2 million compared to $161.9 million for the year ended December 31, 2019 with a $70.3 million increase. The year-over-year increase was primarily due to a higher number of clinical trials, a higher number of patients enrolled in those trials and a higher number of research and development product candidates in the year ended December 31, 2020.\nLoss for the Period\nFor the three months ended December 31, 2020, net loss was $57.8 million, or $0.22 per share, compared to a net loss of $63.9 million, or $0.32 per share, for the three months ended December 31, 2019. Net loss was $303.5 million, or $1.28 per share, for the year ended December 31, 2020 compared to $133.0 million, or $0.66 per share, for the year ended December 31, 2019.\nKey Upcoming Milestones\n\nLegend Biotech’s collaborator, Janssen, anticipates submitting a MAA for cilta-cel for the treatment of adults with RRMM to the EMA in the first half of 2021.\nLegend Biotech intends to use the data from the CARTIFAN-1 study in support of a regulatory submission to the China Center for Drug Evaluation (CDE) seeking approval of cilta-cel for the treatment of adults with RRMM. Legend Biotech expects the submission of the application to occur in the second half of 2021.\nLegend Biotech’s collaborator, Janssen, anticipates submitting a New Drug Application (NDA) to the Japan Ministry of Health, Labor and Welfare (JMHLW) in the second half of 2021 seeking approval of cilta-cel for the treatment of adults with RRMM.\nLegend Biotech expects to initiate its Phase 1 clinical trial of LB1901 in RR TCL inthe United Statesin 2021.\nLegend Biotech, in collaboration with Janssen, intends to present updated data from the CARTITUDE-1 and data from CARTITUDE-2 studies at major medical conferences in 2021.\nLegend Biotech anticipates supporting investigators with publishing a clinical data update from LEGEND-2 study in 2021.\n\nAs the global COVID-19 pandemic continues to evolve, Legend Biotech has continuously monitored the situation in regards to its operations and has put significant measures in place to protect supply chain, operations, employees and the execution of clinical trials. Given the dynamic global situation, Legend Biotech notes that certain clinical trial timelines may be impacted.","news_type":1,"symbols_score_info":{"LEGN":0.9}},"isVote":1,"tweetType":1,"viewCount":265,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":369247330,"gmtCreate":1614052823920,"gmtModify":1634551384439,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"[流泪]&nbsp;","listText":"[流泪]&nbsp;","text":"[流泪]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/369247330","repostId":"1174723019","repostType":4,"repost":{"id":"1174723019","kind":"news","pubTimestamp":1614051562,"share":"https://www.laohu8.com/m/news/1174723019?lang=zh_CN&edition=full","pubTime":"2021-02-23 11:39","market":"us","language":"en","title":"Why Tesla Stock Fell Sharply on Monday<blockquote>为什么特斯拉股价周一大幅下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1174723019","media":"Motley Fool","summary":"Most of the stock's gain this year has been erased.\nWhat happened\nShares of Tesla(NASDAQ:TSLA) were ","content":"<p>Most of the stock's gain this year has been erased.</p><p><blockquote>该股今年的大部分涨幅已被抹去。</blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p> Shares of&nbsp;<b>Tesla</b>(NASDAQ:TSLA)&nbsp;were pummeled on Monday. The stock closed the trading day down about 8.6%</p><p><blockquote>本公司之股份<b>特斯拉</b>（纳斯达克：TSLA）周一遭受重创。该股收盘下跌约8.6%</blockquote></p><p> The automaker's stock decline was likely primarily due to a pullback in the overall market on Monday. Many&nbsp;growth stocks&nbsp;like Tesla were hit particularly hard.</p><p><blockquote>该汽车制造商的股价下跌可能主要是由于周一整体市场的回调。特斯拉等许多成长型股票受到的打击尤其严重。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> Volatility should be expected from Tesla stock. It soared 743% last year as it won over Wall Street's attention. Tesla's sales jumped, and the company demonstrated strong profits. Also likely helping the stock price last year was a big year for growth stocks in general. Many such stocks soared 50% or more in 2020.</p><p><blockquote>预计特斯拉股票会出现波动。由于赢得了华尔街的关注，该股去年飙升了743%。特斯拉的销售额猛增，该公司表现出强劲的利润。总体而言，去年对于成长型股票来说是重要的一年，这也可能有助于股价上涨。许多此类股票在2020年飙升了50%或更多。</blockquote></p><p> But growth stocks were taking a breather on Monday as the&nbsp;<b>Nasdaq Composite</b>&nbsp;fell 2.5%.</p><p><blockquote>但成长型股票周一休息了一下，因为<b>纳斯达克复合材料</b>下跌2.5%。</blockquote></p><p> Most of Tesla's gains this year have evaporated. Shares are now up just 1.5% in 2021.</p><p><blockquote>特斯拉今年的大部分涨幅已经蒸发。2021年股价目前仅上涨1.5%。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Tesla's underlying business will likely continue to grow rapidly this year. Indeed, management guided for vehicle deliveries to increase from about 500,000 in 2020 to more than 750,000 this year.</p><p><blockquote>特斯拉的基础业务今年可能会继续快速增长。事实上，管理层预计车辆交付量将从2020年的约50万辆增加到今年的75万辆以上。</blockquote></p><p> But with a very optimistic business view already priced into Tesla shares, it's difficult to predict where the stock could end up at the end of 2021.</p><p><blockquote>但由于特斯拉股票的定价中已经包含了非常乐观的商业观点，因此很难预测该股在2021年底的最终走势。</blockquote></p><p> There's one thing we can expect with near certainty: plenty more volatility.</p><p><blockquote>有一件事我们几乎可以肯定地预期：波动性会更大。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Tesla Stock Fell Sharply on Monday<blockquote>为什么特斯拉股价周一大幅下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Tesla Stock Fell Sharply on Monday<blockquote>为什么特斯拉股价周一大幅下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-02-23 11:39</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Most of the stock's gain this year has been erased.</p><p><blockquote>该股今年的大部分涨幅已被抹去。</blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p> Shares of&nbsp;<b>Tesla</b>(NASDAQ:TSLA)&nbsp;were pummeled on Monday. The stock closed the trading day down about 8.6%</p><p><blockquote>本公司之股份<b>特斯拉</b>（纳斯达克：TSLA）周一遭受重创。该股收盘下跌约8.6%</blockquote></p><p> The automaker's stock decline was likely primarily due to a pullback in the overall market on Monday. Many&nbsp;growth stocks&nbsp;like Tesla were hit particularly hard.</p><p><blockquote>该汽车制造商的股价下跌可能主要是由于周一整体市场的回调。特斯拉等许多成长型股票受到的打击尤其严重。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> Volatility should be expected from Tesla stock. It soared 743% last year as it won over Wall Street's attention. Tesla's sales jumped, and the company demonstrated strong profits. Also likely helping the stock price last year was a big year for growth stocks in general. Many such stocks soared 50% or more in 2020.</p><p><blockquote>预计特斯拉股票会出现波动。由于赢得了华尔街的关注，该股去年飙升了743%。特斯拉的销售额猛增，该公司表现出强劲的利润。总体而言，去年对于成长型股票来说是重要的一年，这也可能有助于股价上涨。许多此类股票在2020年飙升了50%或更多。</blockquote></p><p> But growth stocks were taking a breather on Monday as the&nbsp;<b>Nasdaq Composite</b>&nbsp;fell 2.5%.</p><p><blockquote>但成长型股票周一休息了一下，因为<b>纳斯达克复合材料</b>下跌2.5%。</blockquote></p><p> Most of Tesla's gains this year have evaporated. Shares are now up just 1.5% in 2021.</p><p><blockquote>特斯拉今年的大部分涨幅已经蒸发。2021年股价目前仅上涨1.5%。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Tesla's underlying business will likely continue to grow rapidly this year. Indeed, management guided for vehicle deliveries to increase from about 500,000 in 2020 to more than 750,000 this year.</p><p><blockquote>特斯拉的基础业务今年可能会继续快速增长。事实上，管理层预计车辆交付量将从2020年的约50万辆增加到今年的75万辆以上。</blockquote></p><p> But with a very optimistic business view already priced into Tesla shares, it's difficult to predict where the stock could end up at the end of 2021.</p><p><blockquote>但由于特斯拉股票的定价中已经包含了非常乐观的商业观点，因此很难预测该股在2021年底的最终走势。</blockquote></p><p> There's one thing we can expect with near certainty: plenty more volatility.</p><p><blockquote>有一件事我们几乎可以肯定地预期：波动性会更大。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/02/22/why-tesla-stock-fell-sharply-on-monday/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.fool.com/investing/2021/02/22/why-tesla-stock-fell-sharply-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174723019","content_text":"Most of the stock's gain this year has been erased.\nWhat happened\nShares of Tesla(NASDAQ:TSLA) were pummeled on Monday. The stock closed the trading day down about 8.6%\nThe automaker's stock decline was likely primarily due to a pullback in the overall market on Monday. Many growth stocks like Tesla were hit particularly hard.\nSo what\nVolatility should be expected from Tesla stock. It soared 743% last year as it won over Wall Street's attention. Tesla's sales jumped, and the company demonstrated strong profits. Also likely helping the stock price last year was a big year for growth stocks in general. Many such stocks soared 50% or more in 2020.\nBut growth stocks were taking a breather on Monday as the Nasdaq Composite fell 2.5%.\nMost of Tesla's gains this year have evaporated. Shares are now up just 1.5% in 2021.\nNow what\nTesla's underlying business will likely continue to grow rapidly this year. Indeed, management guided for vehicle deliveries to increase from about 500,000 in 2020 to more than 750,000 this year.\nBut with a very optimistic business view already priced into Tesla shares, it's difficult to predict where the stock could end up at the end of 2021.\nThere's one thing we can expect with near certainty: plenty more volatility.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":2065,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":382391303,"gmtCreate":1613358439602,"gmtModify":1634553868957,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Useful","listText":"Useful","text":"Useful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/382391303","repostId":"2110026963","repostType":4,"isVote":1,"tweetType":1,"viewCount":375,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164051645,"gmtCreate":1624162333087,"gmtModify":1631889789608,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"🙏🏻🙏🏻🙏🏻","listText":"🙏🏻🙏🏻🙏🏻","text":"🙏🏻🙏🏻🙏🏻","images":[{"img":"https://static.tigerbbs.com/d8dd96436bea0b9c92dd95ae16e70361","width":"1125","height":"1074"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164051645","isVote":1,"tweetType":1,"viewCount":2044,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":166010936,"gmtCreate":1623985232225,"gmtModify":1631889789623,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Read the safety before flying to the moon 🚀🚀🚀","listText":"Read the safety before flying to the moon 🚀🚀🚀","text":"Read the safety before flying to the moon 🚀🚀🚀","images":[{"img":"https://static.tigerbbs.com/bf7f199d98279f47b434137f93979947","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166010936","isVote":1,"tweetType":1,"viewCount":1470,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":161971406,"gmtCreate":1623902995605,"gmtModify":1631889789642,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"一分一毫 清清楚楚","listText":"一分一毫 清清楚楚","text":"一分一毫 清清楚楚","images":[{"img":"https://static.tigerbbs.com/2df10f85bb15a2fd54fd84fa66c51782","width":"1125","height":"2436"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161971406","isVote":1,"tweetType":1,"viewCount":2241,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":169061156,"gmtCreate":1623809414075,"gmtModify":1631889789654,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"Lastly, buy!","listText":"Lastly, buy!","text":"Lastly, buy!","images":[{"img":"https://static.tigerbbs.com/977ef722d3398baaae16beac29e882c8","width":"720","height":"720"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169061156","isVote":1,"tweetType":1,"viewCount":1573,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":185908820,"gmtCreate":1623629234460,"gmtModify":1631889789662,"author":{"id":"3559395309338899","authorId":"3559395309338899","name":"JenYii","avatar":"https://static.tigerbbs.com/529eb98195626d2d61bbc27ff77d02c9","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559395309338899","idStr":"3559395309338899"},"themes":[],"htmlText":"🙏🏻🙏🏻🙏🏻","listText":"🙏🏻🙏🏻🙏🏻","text":"🙏🏻🙏🏻🙏🏻","images":[{"img":"https://static.tigerbbs.com/810dfc226dde7db2efc68b3b69c713e8","width":"1125","height":"1100"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185908820","isVote":1,"tweetType":1,"viewCount":700,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}